



US009149470B2

(12) **United States Patent**
Yan et al.

(10) **Patent No.:** **US 9,149,470 B2**
(45) **Date of Patent:** **Oct. 6, 2015**

(54) **MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE**

(75) Inventors: **John Yan**, Los Gatos, CA (US); **Xiaoxia Zheng**, Mountain View, CA (US); **Vinayak D. Bhat**, Cupertino, CA (US)

(73) Assignee: **ELIXIR MEDICAL CORPORATION**, Sunnyvale, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 575 days.

(21) Appl. No.: **13/302,588**

(22) Filed: **Nov. 22, 2011**

(65) **Prior Publication Data**

US 2012/0071500 A1 Mar. 22, 2012

Related U.S. Application Data

(63) Continuation of application No. 12/046,024, filed on Mar. 11, 2008, now Pat. No. 8,088,789, which is a continuation-in-part of application No. 11/854,312, filed on Sep. 12, 2007, now Pat. No. 7,867,988.

(60) Provisional application No. 60/825,531, filed on Sep. 13, 2006.

(51) **Int. Cl.**

A61K 31/4741 (2006.01)
A61K 31/4525 (2006.01)
A61K 31/365 (2006.01)
A61K 31/436 (2006.01)
A61K 31/427 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 31/4525** (2013.01)

(58) **Field of Classification Search**

CPC A61K 31/4525; A61K 31/365; A61K 31/436; A61K 31/427
USPC 514/291
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,929,992 A 12/1975 Sehgal et al.
5,595,756 A 1/1997 Bally et al.
5,646,160 A 7/1997 Morris et al.
5,665,772 A 9/1997 Cottens et al.
5,728,710 A 3/1998 Luego
5,957,975 A 9/1999 Lafont et al.
5,985,890 A 11/1999 Cottens et al.
6,001,998 A 12/1999 Nishida et al.
6,015,815 A 1/2000 Mollison
6,187,568 B1 2/2001 Nishida et al.
6,273,913 B1 8/2001 Wright et al.
6,585,764 B2 7/2003 Wright et al.
6,641,611 B2 11/2003 Jayaraman
6,805,703 B2 10/2004 McMorro
7,025,734 B1 4/2006 Ellis et al.
7,056,942 B2 6/2006 Hildesheim et al.
7,820,812 B2 10/2010 Viswanath et al.
7,867,988 B2 1/2011 Yan et al.
2001/0027340 A1 10/2001 Wright et al.

2001/0029351 A1 10/2001 Falotico et al.
2002/0005206 A1 1/2002 Falotico et al.
2002/0007213 A1 1/2002 Falotico et al.
2002/0082680 A1 6/2002 Shanley et al.
2002/0123505 A1 9/2002 Mollison et al.
2003/0099712 A1 5/2003 Jayaraman
2003/0129215 A1 7/2003 Mollison et al.
2004/0072857 A1 4/2004 Waugh et al.

(Continued)

FOREIGN PATENT DOCUMENTS

EP 1236478 A1 9/2002
EP 1588727 A1 10/2005

(Continued)

OTHER PUBLICATIONS

Dickman DA, Ding H, Li Q, Nilus AM, Balli DJ, Ballaron SJ, Trevillyan JM, Smith ML, Seif LS, Kim K, Sarthy A, Goldman RC, Plattner JJ, Bennani YL, "Antifungal Rapamycin Analogues with Reduced Immunosuppressive Activity," *Bioorganic & Medicinal Letters*, 2000, 10: 1405-1408.*

Multiple Sclerosis Information Page from NINDS, pp. 1-4. Accessed Mar. 14, 2010.

Sporn, et al. Chemoprevention of cancer. *Carcinogenesis*. Mar. 2000;21(3):525-30.

Sriram, et al. Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. *Ann Neurol*. Dec. 2005;58(6):939-45.

Steinman, et al. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. *Ann Neurol*. Jul. 2006;60(1):12-21.


(Continued)

Primary Examiner — Julie Ha

(74) *Attorney, Agent, or Firm* — Wilson Sonsini Goodrich & Rosati

(57) **ABSTRACT**

The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the general formula:



15 Claims, 111 Drawing Sheets

(56)

References Cited

U.S. PATENT DOCUMENTS

2005/0033417	A1	2/2005	Borges et al.
2005/0101624	A1	5/2005	Betts et al.
2005/0152842	A1	7/2005	Li et al.
2005/0175660	A1	8/2005	Mollison et al.
2005/0208095	A1	9/2005	Hunter et al.
2005/0209244	A1	9/2005	Prescott et al.
2005/0239178	A1	10/2005	Ruppen et al.
2006/0094744	A1	5/2006	Maryanoff et al.
2006/0229711	A1	10/2006	Yan et al.
2007/0015697	A1	1/2007	Peyman
2007/0059336	A1	3/2007	Hughes et al.
2007/0207186	A1	9/2007	Scanlon et al.
2008/0086198	A1	4/2008	Owens et al.
2008/0234309	A1	9/2008	Yan et al.
2011/0097364	A1	4/2011	Yan et al.
2012/0093891	A1	4/2012	Yan et al.

FOREIGN PATENT DOCUMENTS

JP	2005-537854	12/2005
WO	WO 93/16189 A1	8/1993
WO	WO 94/02136 A1	2/1994
WO	WO 94/09010 A1	4/1994
WO	WO 94/12655 A1	6/1994
WO	WO 96/06847 A1	3/1996
WO	WO 96/41807 A1	12/1996
WO	WO 98/07415 A2	2/1998
WO	WO 98/07415 A3	5/1998
WO	WO 01/87263 A2	11/2001
WO	WO 01/87342 A2	11/2001
WO	WO 01/87372 A1	11/2001
WO	WO 01/87373 A1	11/2001
WO	WO 01/87374 A1	11/2001
WO	WO 01/87375 A1	11/2001
WO	WO 01/87376 A1	11/2001
WO	WO 01/87263 A3	4/2002
WO	WO 01/87342 A3	4/2002
WO	WO 02/056790 A2	7/2002
WO	WO 02/065947 A2	8/2002
WO	WO 02/56790 A3	1/2003
WO	WO 02/065947 A3	9/2003
WO	WO 03/064383 A2	10/2003
WO	WO 03/064383 A3	1/2004
WO	WO 2006/116716 A2	11/2006
WO	WO 2006/116716 A3	5/2007
WO	WO 2008/033956 A2	3/2008
WO	WO 2008/033956 A9	9/2008
WO	WO 2008/033956 A3	11/2008

OTHER PUBLICATIONS

Office action dated Mar. 29, 2011 for U.S. Appl. No. 12/046,024.
Office action dated May 3, 2012 for U.S. Appl. No. 13/333,526.
Office action dated Jul. 25, 2012 for U.S. Appl. No. 13/333,573.
Office action dated Jul. 31, 2009 for U.S. Appl. No. 11/854,312.
Definition of analog from <http://cancerweb.ncl.ac.uk/omd/about.html>, pp. 1-5. Accessed Jul. 7, 2005.
European search report and opinion dated Feb. 20, 2012 for EP Application No. 11191788.6.
European search report and opinion dated Apr. 5, 2012 for EP Application No. 08731883.8.
Nishida, et al. Generation of novel rapamycin structures by microbial manipulations. *Journal of Antibiotics*. 1995; 48(7):657-666.
European search report and search opinion dated Feb. 4, 2014 for EP Application No. 13181253.9.
U.S. Appl. No. 13/333,526, filed Dec. 21, 2011, Yan et al.
U.S. Appl. No. 13/333,573, filed Dec. 21, 2011, Yan et al.
Autoimmune disorder. *MedlinePlus*. p. 1-3. Accessed Jan. 18, 2012.
Cai, et al. In Vitro Metabolic Study of Temsirolimus: Preparation, Isolation, and Identification of the Metabolites. *DMD*, Sep. 2007, 35(9):1554-1563.
Definition of metabolite from www.answers.com/topic/metabolite, pp. 1-2. Accessed Jul. 29, 2009.

Dupont, et al. The Evolving Role of Sirolimus in Renal Transplantation. *QJMed*, 2003, 96(6):401-409.
Edwards et al., "The Rapamycin-binding Domain of the Protein Kinase Mammalian Target of Rapamycin Is a Destabilizing Domain", *J. Biol. Chem.*, May 4, 2007, 282(18):13395-13401.
European search report and opinion dated Oct. 13, 2010 for EP Application No. 07842371.2.
Fingar, et al. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. *Oncogene*, Apr. 19, 2004, 23(18):3151-3171.
Gallant-Haidner et al., "Pharmacokinetics and Metabolism of Sirolimus", *Therapeutic Drug Monitoring*, Feb. 2000, 22(1):31-35.
Grinfeld et al., "Acid Catalyzed Functionalization of Rapamycin", *Tetrahedron Letters*, Sep. 12, 1994, 35(37):6835-6838.
Herpes Zoster Ophthalmicus from Merck manual, pp. 1-2. Accessed Mar. 23, 2011.
Hultsch, et al. The Effect of the Immunophilin Ligands Rapamycin and FK506 on Proliferation of Mast Cells and other hematopoietic cell lines. *Mol. Biol. Cell*, Sep. 1992, 3(9): 981-987.
International preliminary report on patentability dated Oct. 18, 2011 for PCT/US2008/056501.
International search report and written opinion dated Jun. 24, 2008 for PCT/US2008/056501.
International search report dated Sep. 29, 2008 for PCT/US2007/078317.
Kuhnt et al., "Microbial Conversion of Rapamycin", *Enzyme & Microbial Tech.*, Nov. 1, 1997, 21(6):405-412.
Leung et al., "Pharmacokinetics and Metabolic Disposition of Sirolimus in Healthy Male Volunteers After a Single Oral Dose", *Ther. Drug Monit.*, Feb. 2006, 28(1):51-61.
Lhoest, et al. In vitro immunosuppressive activity of tacrolimus dihydrodiol precursors obtained by chemical oxidation and identification of a new metabolite of SDZ-RAD by electrospray and electrospray-linked scan mass spectrometry. *J. Mass Spectrom.*, 2001, 36:889-901.
Lhoest, et al. Isolation from pig liver microsomes, identification by tandem mass spectrometry and in vitro immunosuppressive activity of an SDZ-RAD 17,18,19,20,21,22-tris-epoxide. *J. Mass Spectrom.*, 2000, 35:454-460.
Luengo, et al. Structure-activity studies of rapamycin analogs: evidence that the C-7 methoxy group is part of the effector domain and positioned at the FKBP12-FRAP interface. *Chem. & Biol.*, 1995, 2:471-481.
Marks, A.R., "Rapamycin: Signaling in Vascular Smooth Muscle", *Transplantation Proc.*, 2003, 35(Suppl. 3A):231S-233S.
Nickmilder, et al. Isolation and identification of new rapamycin dihydrodiol metabolites from dexamethasone-induced rat liver microsomes. *Xenobiotica*, 1997, 27(9):869-883.
Onuma, et al. MAHOROBA, first-in-man study: 6-month results of a biodegradable polymer sustained release tacrolimus-eluting stent in de novo coronary stenoses. *Eur. Heart J.*, 2009, 30(12):1477-1485.
Sedrani, et al. Dihydroxylation of the Triene Subunit of Rapamycin. *J. Org. Chem.*, 1998, 63:10069-10073.
Supplementary European Search Report dated Sep. 29, 2010 for EP 07842371.
Trepanier, et al. Rapamycin: Distribution, Pharmacokinetics and Therapeutic Range Investigations: An Update. *Clin. Biochem.*, Jul. 1998, 31(5):345-351.
Auerbach, et al. Angiogenesis assays: problems and pitfalls. *Cancer Metastasis Rev.* 2000;19(1-2):167-72.
Cell proliferation definition. Accessed Jul. 28, 2009. www.cancer.gov/Templates/db_alpha.aspx?Cdrid=46479.
Chirality and thalidomide. [Www.skingenious.com/faq.html](http://www.skingenious.com/faq.html). Accessed Jul. 29, 2009.
Definition of inhibit. [Www.dictionary.com](http://www.dictionary.com). Accessed Jul. 29, 2009.
Definition of isomer. [Www.answers.com/topic/isomer](http://www.answers.com/topic/isomer). Accessed Jul. 29, 2009.
Gura. Systems for identifying new drugs are often faulty. *Science*. Nov. 7, 1997;278(5340):1041-2.
Han. Targeted prodrug design to optimize drug delivery. *AAPS Pharmsci.* 2000; 2(1):1-11.

(56)

References Cited

OTHER PUBLICATIONS

Hensley. Zyrtec looks in mirror and sees xyzal. Blogs.wsj.com/health/2007/05/29/zyrtec-looks-in-mirror-and-sees-xyzal/. Accessed Jul. 29, 2009.

Jain. Barriers to drug delivery in solid tumors. Sci Am. Jul. 1994;271(1):58-65.

Marketletter. Drug-coated stent blocks restenosis; brief article. 0951-3175 2000—IAC-ACC—No. 68770167.

Marx, et al. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res. 1995; 76(3):412-417.

Merck manual. Bowen's disease. Accessed Jun. 1, 2009.

Merck manual. Clinical aspects of cancer. Accessed Mar. 5, 2008.

Merck manual. Introduction to asthma. Accessed Jul. 28, 2009.

Merck manual. Introduction to Cancer. Accessed Mar. 5, 2008.

Merck manual. Kaposi's sarcoma. Accessed Jun. 1, 2009.

Merck manual. Rheumatoid arthritis. Accessed Jul. 29, 2009.

Merck manual. Squamous cell carcinoma. Accessed Jun. 1, 2009.

More. Xyzal: state of the art antihistamine. Accessed Jul. 29, 2009.

Morice, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl J Med. 2002; 346(23):1773-1780.

Poon, et al. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest. 1996; 98:2277-2283.

Simonsen, et al. Cardiology market continues rapid growth in a broad technology front. The BBI newsletter. 1999; 22(4):1049-4316.

Sousa, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation. 2001; 104(17):2007-2011.

Suzuki, et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001; 104:1188-1193.

Vignot, et al. mTOR-targeted therapy of cancer with rapamycin derivatives. Annals of Oncology. 2005; 16:525-537.

Vippagunta, et al. Crystalline solids. Advanced Drug Delivery Reviews. 2001; 48:3-26.

* cited by examiner

Fig. 1




Fig. 2b




Fig. 2a




Fig. 2d




Fig. 2c




Fig. 2f




Fig. 2e




Fig. 2h




Fig. 2g




Fig. 2j




Fig. 2i




Fig. 2l




Fig. 2k




Fig. 2n




Fig. 2m




Fig. 2p




Fig. 2o




Fig. 2r




Fig. 2q




Fig. 2t




Fig. 2s




Fig. 2x




Fig. 2w




Fig. 2ab




Fig. 2aa




Fig. 2ad




Fig. 2ac




Fig. 2ah




Fig. 2ag




Fig. 2aj




Fig. 2ai




Fig. 2an




Fig. 2am




Fig. 2ap




Fig. 2ao




Fig. 2ar




Fig. 2aq




Fig. 2at




Fig. 2as




Fig. 2av




Fig. 2au




Fig. 2ax




Fig. 2aw




Fig. 2az




Fig. 2ay




Fig. 2bb




Fig. 2ba




Fig. 2bd




Fig. 2bc




Fig. 2bf




Fig. 2be




Fig. 2bh




Fig. 2bg




Fig. 2bj




Fig. 2bi




Fig. 2bi




Fig. 2bk




Fig. 2bn




Fig. 2bm




Fig. 2bp




Fig. 2bo




Fig. 2br




Fig. 2bq




Fig. 2bt




Fig. 2bs




Fig. 2bv




Fig. 2bu




Fig. 2bx




Fig. 2bw




Fig. 2cb




Fig. 2ca




Fig. 2cd




Fig. 2cc




Fig. 2cf




Fig. 2ce




Fig. 2ch




Fig. 2cg




Fig. 2cj




Fig. 2ci




Fig. 2cl




Fig. 2ck




Fig. 2cn




Fig. 2cm




Fig. 2cp




Fig. 2co




Fig. 2cr




Fig. 2cq




Fig. 2ct




Fig. 2cs




Fig. 2cv




Fig. 2cu




Fig. 2cx




Fig. 2cw




Fig. 2cz




Fig. 2cy




Fig. 2db




Fig. 2da




Fig. 2dd




Fig. 2dc




Fig. 2df




Fig. 2de




Fig. 2dh




Fig. 2dg




Fig. 2dj




Fig. 2di




Fig. 2dl




Fig. 2dk




Fig. 2dm




Fig. 2dn




Fig. 2dp




Fig. 2do




Fig. 2dr




Fig. 2dq




Fig. 2dt




Fig. 2ds




Fig. 2dv




Fig. 2du




Fig. 2dx




Fig. 2dw




Fig. 2dz




Fig. 2dy




Fig. 2eb




Fig. 2ea




Fig. 2ed




Fig. 2ec




Fig. 2ef




Fig. 2ee




Fig. 2eI




Fig. 2ek




Fig. 2em




Fig. 2em




Fig. 2ep




Fig. 2eo




Fig. 2er




Fig. 2eq




Fig. 2et




Fig. 2es




Fig. 2ev




Fig. 2eu




Fig. 2ez




Fig. 2ey




Fig. 2fb




Fig. 2fa




Fig. 2fd




Fig. 2fc




Fig. 2ff




Fig. 2fe




Fig. 2fh




Fig. 2fg




Fig. 2fj




Fig. 2fi




Fig. 2fl




Fig. 2fk




Fig. 2fn




Fig. 2fm




Fig. 2fp




Fig. 2fo




Fig. 2fv




Fig. 2fu




Fig. 3




Fig. 4




Fig. 5




Fig. 6a




Fig. 6b




Fig. 7a




Fig. 7b





Fig. 8



- One Hr Exposure to Rapamycin
- ▲ Three Hr Exposure to Rapamycin
- Eight Hr Exposure to Rapamycin
- One Hr Exposure to Compound AR
- △ Three Hr Exposure to Compound AR
- Eight Hr Exposure to Compound AR

Fig. 9




Fig. 10




Fig. 11




Fig. 12a




Fig. 12b




Fig. 13





Fig. 14






Fig. 16




FIG. 17A






FIG. 17B



Preparative
 HPLC → Individual pure product

FIG. 18A





FIG. 18B



Preparative
 HPLC → Individual
 pure product

1

MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE

CROSS-REFERENCES TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 12/046,024, filed Mar. 11, 2008, which claims the benefit of U.S. application Ser. No. 11/854,312, filed Sep. 12, 2007, which claims the benefit of U.S. Provisional Application No. 60/825,531, filed Sep. 13, 2006, the full disclosures of which are incorporated by reference herein in their entirety.

STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

Not Applicable

REFERENCE TO A "SEQUENCE LISTING," A TABLE, OR A COMPUTER PROGRAM LISTING APPENDIX SUBMITTED ON A COMPACT DISK


Not Applicable

FIELD OF THE INVENTION

The present invention relates to structures of demethyl, hydroxyl, demethylhydroxyl, epoxide, N-oxide, opened hemiketal ring and seco-macrocyclic lactones, their synthesis, pharmaceutical compositions and use for systemic and site specific therapeutic applications.

BACKGROUND

Rapamycin (Sirolimus) is a 31-member natural macrocyclic lactone [C₅₁H₇₉N₁O₁₃; MWt=914.2] produced by *Streptomyces hygroscopicus* and found in the 1970s (U.S. Pat. No. 3,929,992 ; 3,993,749). Rapamycin (structure shown below) was approved by the Food and Drug Administration (FDA) for the prophylaxis of renal transplant rejection in 1999.



2

Rapamycin resembles tacrolimus (binds to the same intracellular binding protein or immunophilin known as FKBP-12) but differs in its mechanism of action. Whereas tacrolimus and cyclosporine inhibit T-cell activation by blocking lymphokine (e.g., IL2) gene transcription, sirolimus inhibits T-cell activation and T lymphocyte proliferation by binding to mammalian target of rapamycin (mTOR). Rapamycin can act in synergy with cyclosporine or tacrolimus in suppressing the immune system.

Rapamycin is also useful in preventing or treating systemic lupus erythematosus [U.S. Pat. No. 5,078,999], pulmonary inflammation [U.S. Pat. No. 5,080,899], insulin dependent diabetes mellitus [U.S. Pat. No. 5,321,009], skin disorders, such as psoriasis [U.S. Pat. No. 5,286,730], bowel disorders [U.S. Pat. No. 5,286,731], smooth muscle cell proliferation and intimal thickening following vascular injury [U.S. Pat. Nos. 5,288,711 and 5,516,781], adult T-cell leukemia/lymphoma [European Patent Application 525,960 A1], ocular inflammation [U.S. Pat. No. 5,387,589], malignant carcinomas [U.S. Pat. No. 5,206,018], cardiac inflammatory disease [U.S. Pat. No. 5,496,832], anemia [U.S. Pat. No. 5,561,138] and increase neurite outgrowth [Parker, E. M. et al, *Neuropharmacology* 39, 1913-1919, 2000].

Although rapamycin can be used to treat various disease conditions, the utility of the compound as a pharmaceutical drug has been limited by its very low and variable bioavailability and its high immunosuppressive potency and potential high toxicity. Also, rapamycin is only very slightly soluble in water. To overcome these problems, prodrugs and analogues of the compound have been synthesized. Water soluble prodrugs prepared by derivatizing rapamycin positions 31 and 42 (formerly positions 28 and 40) of the rapamycin structure to form glycinate, propionate, and pyrrolidino butyrate prodrugs have been described (U.S. Pat. No. 4,650,803). Some of the analogues of rapamycin described in the art include monoacyl and diacyl analogues (U.S. Pat. No. 4,316,885), acetal analogues (U.S. Pat. No. 5,151,413), silyl ethers (U.S. Pat. No. 5,120,842), hydroxyesters (U.S. Pat. No. 5,362,718), as well as alkyl, aryl, alkenyl, and alkynyl analogues (U.S. Pat. Nos. 5,665,772; 5,258,389; 6,384,046; WO 97/35575).


Prodrugs and analogues of rapamycin are synthesized by chemical synthesis, where additional synthetic steps are required to protect and deprotect certain positions. Analogues can also be synthesized biologically, where the *Streptomyces* strain is genetically modified to produce these analogues of rapamycin. The analogues need to maintain necessary positions for protein binding or other cellular interactions and not generate steric hindrance in order to preserve its activity. The safety of these analogues requires extensively testing by series of preclinical and clinical experimentations.

The present invention comprises novel macrocyclic lactones and novel uses for macrocyclic lactones, where the compositions can be synthesized chemically or biologically and which preserve at least some immunosuppressive, anti-proliferative, anti-fungal and anti-tumor properties for use in systemic and site specific applications.


BRIEF SUMMARY OF THE INVENTION

In one embodiment, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula:


3




wherein $R^1, R^2, R^3, R^5, R^6, R^8, M^1, M^2, M^3, M^4, M^5, M^6$ and M^7 are each independently a member selected from the group consisting of H, C_{1-6} alkyl, OH and C_{1-6} hydroxyalkyl; R^4, R^7 and R^9 are each independently selected from the group consisting of C_{1-6} alkoxy and OH; R^{10} is a member selected from the group consisting of H, —OH, —OP(O)Me₂,



—O—(CH₂)_n—OH and —O—(CH₂)_m—O—(CH₂)_o—CH₃, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L¹ and L⁴ are independently selected from the group consisting of:



wherein each M⁸ is independently a member selected from the group consisting of C_{1-6} alkyl, OH and C_{1-6} hydroxyalkyl; each of L² and L³ are independently selected from the group consisting of:



and salts, hydrates, isomers, metabolites, N-oxides and prodrugs thereof.


In a second embodiment, the present invention provides a device for intracorporeal use, the device comprising an implant; and at least one source of a compound of the present invention.

In a third embodiment, the present invention provides a method of inhibiting cell proliferation by administering to a


4

subject in need thereof, a therapeutically effective amount of a compound of the present invention.


In a fourth embodiment, the present invention provides macrocyclic lactone compounds of the following formula:




wherein $R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, M^1, M^2, M^3, M^4, M^5, M^6, M^7, L^1, L^2, L^3$ and L^4 are as described above; with the proviso that when R^1, R^6, R^8, M^6 and M^7 are Me, $R^3, R^5, M^1, M^2, M^3, M^4$ and M^5 are H, R^4, R^7 and R^9 are OMe, R^{10} and M^8 are OH, L^2 and L^3 are —CH=CH—, and L^1 and L^4 are



R^2 is other than OH; with the proviso that when R^1, R^6, R^8, M^6 and M^7 are Me, $R^2, R^3, R^5, M^1, M^2, M^3, M^4$ and M^5 are H, R^4, R^7 and R^9 are OMe, R^{10} and M^8 are OH, L^2 and L^3 are —CH=CH—, and L^1 and L^4 are




R^4 is other than OH; with the proviso that when R^1, R^6, R^8, M^6 and M^7 are Me, $R^2, R^3, R^5, M^1, M^2, M^3, M^4$ and M^5 are H, R^4, R^7 and R^9 are OMe, R^{10} and M^8 are OH, L^2 and L^3 are —CH=CH—, and L^1 and L^4 are




R^9 is other than OH; with the proviso that when R^1, R^6, R^8, M^6 and M^7 are Me, $R^2, R^3, R^5, M^1, M^2, M^3, M^4$ and M^5 are H, R^4, R^7 and R^9 are OMe, R^{10} and M^8 is OH, L^2 and L^3 are —CH=CH—, and L^1 and L^4 are

5



R^{10} is other than OH, $-\text{OP}(\text{O})\text{Me}_2$,




$-\text{O}-(\text{CH}_2)_m-\text{OH}$ and $-\text{O}-(\text{CH}_2)_m-\text{O}-(\text{CH}_2)_o-$
 CH_3 ; and salts, hydrates, isomers, metabolites, N-oxides
 and prodrugs thereof.

In a fifth embodiment, the present invention provides a
 method of making a compound of the present invention, the
 method comprising contacting a macrocyclic lactone with an
 acid to replace an alkoxy group with a nucleophile, thereby
 making a compound of the present invention.

In a sixth embodiment, the present invention provides a
 method of making a compound of the present invention, the
 method comprising contacting a macrocyclic lactone with an
 epoxidation agent to modify an alkene group to an epoxide,
 thereby making a compound of the present invention.


In a seventh embodiment, the present invention provides a
 pharmaceutical composition including a pharmaceutically
 acceptable excipient and a compound of the formula:



wherein $R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, M^1, M^2, M^3,$
 $M^4, M^5, M^6, M^7, L^1, L^2, L^3$ and L^4 are as described above;
 and salts, hydrates, isomers, metabolites, N-oxides and
 prodrugs thereof.

In an eighth embodiment, the present invention provides a
 pharmaceutical composition including a pharmaceutically
 acceptable excipient and a compound of the formula:

6



wherein $R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, M^1, M^2, M^3,$
 $M^4, M^5, M^6, M^7, L^1, L^2, L^3$ and L^4 are as described above;
 and salts, hydrates, isomers, metabolites, N-oxides and
 prodrugs thereof.

In a ninth embodiment, the present invention provides a
 method of treating an ophthalmic condition or disease by
 administering to a subject in need thereof, a therapeutically
 effective amount of a compound of the present invention.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the structure of macrocyclic lactones with
 some potential sites for chemical modifications to provide
 compounds of the present invention. Areas marked with a
 square are sites for demethylation, and areas marked by A
 circle are sites for hydroxylation and C=C sites (C17=C18,
 C19=C20, C21=C22, C29=C30) are sites for epoxida-
 tion.

FIG. 2A-2FV shows compounds of the present invention.

FIG. 3 shows an example of stent configuration having an
 expandable structure.

FIG. 4 shows a preparative HPLC chromatogram of Com-
 pound AR.

FIG. 5 shows a Proton-NMR spectra of Compound AR.

FIG. 6 shows results of liquid chromatography and mass
 spectra of Compound AR.

FIG. 7(a) shows an analytical HPLC chromatogram of
 Compound AR.

FIG. 7(b) shows an analytical HPLC chromatogram of
 Compound AR with isomers.

FIG. 8 shows percentage proliferation of human smooth
 muscle cells after exposure to varying concentrations of rapa-
 mycin and Compound AR.

FIG. 9 shows quantitative coronary angiography (QCA)
 stenosis of the Compound AR eluting stent as compared to
 rapamycin eluting Cypher stent after 28 day implantation in a
 porcine coronary artery model.

FIG. 10 shows tissue concentration of Compound AR at
 different time points in a porcine coronary artery model.

FIG. 11 shows percentage of Compound AR released from
 the stent in a porcine coronary artery model.

FIG. 12(a) shows inhibition of IL-6, MMP-9 and MCP-1
 released by activated macrophages by exposure to macrocy-
 clic lactone Compound AR and Sirolimus at 10 nM concen-
 tration.

FIG. 12(b) shows inhibition of IL-10 released by activated macrophages by exposure to macrocyclic lactone Compound AR and Sirolimus at 10 nM concentration

FIG. 13 shows percentage proliferation of human smooth muscle cells after exposure to varying concentrations of 17,18-29,30-bis-epoxide macrocyclic lactone and Compound AR.

FIG. 14 shows the synthesis of 16-O-demethyl macrocyclic lactone of the present invention.

FIGS. 15A-15B show the synthesis of 19, 20 bis-hydroxy macrocyclic lactone.

FIG. 16 shows the synthesis of 17,18-29,30-bis epoxide macrocyclic lactone.

FIGS. 17A-17B show the synthesis of 31-hydroxyl, 44-hydroxyl and 47-hydroxyl macrocyclic lactones.

FIGS. 18A-18B show the synthesis of 43-hydroxyl and 47-hydroxyl macrocyclic lactones.

DETAILED DESCRIPTION OF THE INVENTION

I. Definitions

As used herein, the term “acid” refers to any chemical compound that, when dissolved in water, gives a solution with a pH less than 7.0. Acids are generally described as a compound which donates a hydrogen ion (H⁺) (Bronsted-Lowry) or as an electron-pair acceptor (Lewis acid). Acids useful in the present invention include, but are not limited to, HCl, H₂SO₄, HNO₃ and acetic acid. One of skill in the art will appreciate that other acids are useful in the present invention.

As used herein, “administering” refers to systemic and local administration or a combination thereof such as oral administration, administration as a suppository, topical contact, parenteral, intravascular, intravenous, intraperitoneal, intramuscular, intralesional, intranasal, pulmonary, mucosal, transdermal, subcutaneous administration, intrathecal, intraocular, intravitreal administration, delivery through a temporary device such as catheter, porous balloon, delivery through implant such as polymeric implant, osmotic pump, prosthesis such as drug eluting stents or others to the subject. One of skill in the art will appreciate that other modes and methods of administering the compounds of the present invention are useful in the present invention.

As used herein, the term “alkoxy” refers to alkyl with the inclusion of an oxygen atom, for example, methoxy, ethoxy, etc. “Halo-substituted-alkoxy” is as defined for alkoxy where some or all of the hydrogen atoms are substituted with halogen atoms. For example, halo-substituted-alkoxy includes trifluoromethoxy, etc. One of skill in the art will appreciate that other alkoxy groups are useful in the present invention.

As used herein, the term “alkyl” refers to a straight or branched, saturated, aliphatic radical having the number of carbon atoms indicated. For example, C₁-C₆ alkyl includes, but is not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, iso-propyl, iso-butyl, sec-butyl, tert-butyl, etc. One of skill in the art will appreciate that other alkyl groups are useful in the present invention.

As used herein, the term “hydroxyalkyl” refers to alkyl as defined above where at least one of the hydrogen atoms is substituted with a hydroxy group. For example, hydroxyalkyl includes hydroxy-methyl, hydroxy-ethyl (1- or 2-), hydroxy-propyl (1-, 2- or 3-), hydroxy-butyl (1-, 2-, 3- or 4-), hydroxy-pentyl (1-, 2-, 3-, 4- or 5-), hydroxy-hexyl (1-, 2-, 3-, 4-, 5- or 6-), 1,2-dihydroxyethyl, and the like. One of skill in the art will appreciate that other hydroxyalkyl groups are useful in the present invention.

As used herein, the term “body lumen” refers to the lining or cavity of an artery, vein or an organ.

As used herein, the term “contacting” refers to the process of bringing into contact at least two distinct species such that they can react. It should be appreciated, however, that the resulting reaction product can be produced directly from a reaction between the added reagents or from an intermediate from one or more of the added reagents which can be produced in the reaction mixture.

As used herein, the term “hydrate” refers to a compound that is complexed to at least one water molecule. The compounds of the present invention can be complexed with from 1 to 100 water molecules.

As used herein, the term “implant” refers to a medical device inserted into a body in order to treat a condition. Implants include, but are not limited to, drug-eluting devices.

As used herein, the terms “inhibition”, “inhibits” and “inhibitor” refer to a compound that prohibits, reduces, diminishes or lessens, or to a method of prohibiting, reducing, diminishing or lessening a specific action or function.

As used herein, the term “intracorporeal” refers to an mammalian body.

As used herein, the term “isomer” refers to compounds of the present invention that possess asymmetric carbon atoms (optical centers) or double bonds, the racemates, diastereomers, enantiomers, geometric isomers, structural isomers and individual isomers are all intended to be encompassed within the scope of the present invention.

As used herein, the term “organ” refers to any organ of a mammal, such as, but not limited to, heart, lungs, brain, eye, stomach, spleen, bones, pancreas, kidneys, liver, intestines, uterus, colon, ovary, blood, skin, muscle, tissue, prostate, mammary and bladder. One of skill in the art will appreciate that other organs are useful in the present invention.

As used herein, the term “peracid” refers to an acid in which an acidic —OH group has been replaced by an —OOH group. Peracids can be peroxy-carboxylic acids of the formula R—C(O)—OOH, where the R group can be groups such as H, alkyl, alkene or aryl. Peracids include, but are not limited to, peroxy-acetic acid and meta-chloro-peroxybenzoic acid (MCPBA). One of skill in the art will appreciate that other peracids are useful in the present invention.

As used herein, the term “peroxide” refers to a compound containing an oxygen-oxygen single bond. Examples of peroxides include, but are not limited to, hydrogen peroxide. One of skill in the art will appreciate that other peroxides are useful in the present invention.

As used herein, the term “pharmaceutically acceptable excipient” refers to a substance that aids the administration of an active agent to and absorption by a subject. Pharmaceutical excipients useful in the present invention include, but are not limited to, polymers, solvents, antioxidants, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors, stabilizers, colorants, metals, ceramics and semi-metals. See below for additional discussion of pharmaceutically acceptable excipients. One of skill in the art will recognize that other pharmaceutical excipients are useful in the present invention.

As used herein, the term “polymer” refers to a molecule composed of repeating structural units, or monomers, connected by covalent chemical bonds. Polymers useful in the present invention are described below. One of skill in the art will appreciate that other polymers are useful in the present invention.

As used herein, the term “prodrug” refers to compounds which are capable of releasing the active agent of the methods of the present invention, when the prodrug is administered to a mammalian subject. Release of the active ingredient occurs in vivo. Prodrugs can be prepared by techniques known to one skilled in the art. These techniques generally modify appro-

9

appropriate functional groups in a given compound. These modified functional groups however regenerate original functional groups by routine manipulation or in vivo. Prodrugs of the active agents of the present invention include active agents wherein a hydroxy, amidino, guanidino, amino, carboxylic or a similar group is modified.

As used herein, the term "salt" refers to acid or base salts of the compounds used in the methods of the present invention. Illustrative examples of pharmaceutically acceptable salts are mineral acid (hydrochloric acid, hydrobromic acid, phosphoric acid, and the like) salts, organic acid (acetic acid, propionic acid, glutamic acid, citric acid and the like) salts, quaternary ammonium (methyl iodide, ethyl iodide, and the like) salts. Additional information on suitable pharmaceutically acceptable salts can be found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, which is incorporated herein by reference.

Pharmaceutically acceptable salts of the acidic compounds of the present invention are salts formed with bases, namely cationic salts such as alkali and alkaline earth metal salts, such as sodium, lithium, potassium, calcium, magnesium, as well as ammonium salts, such as ammonium, trimethyl-ammonium, diethylammonium, and tris-(hydroxymethyl)-methyl-ammonium salts.

Similarly acid addition salts, such as of mineral acids, organic carboxylic and organic sulfonic acids, e.g., hydrochloric acid, methanesulfonic acid, maleic acid, are also possible provided a basic group, such as pyridyl, constitutes part of the structure.

The neutral forms of the compounds may be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention.

As used herein, the term "source" refers to a location on the device of the present invention providing a supply of the compound of the present invention or a supply of a therapeutic agent. The device of the present invention can have more than one source, such as a first and second. Each source can have a different compound and composition and be used to treat a different indication.

As used herein, the term "subject" refers to animals such as mammals, including, but not limited to, primates (e.g., humans), cows, sheep, goats, horses, pigs, dogs, cats, rabbits, rats, mice and the like. In certain embodiments, the subject is a human.

As used herein, the term "therapeutic agent" refers to any agent, compound or biological molecule that has a therapeutic effect on the patient to whom the therapeutic agent is administered.

As used herein, the terms "therapeutically effective amount or dose" or "therapeutically sufficient amount or dose" or "effective or sufficient amount or dose" refer to a dose that produces therapeutic effects for which it is administered. The exact dose will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (see, e.g., Lieberman, *Pharmaceutical Dosage Forms* (vols. 1-3, 1992); Lloyd, *The Art, Science and Technology of Pharmaceutical Compounding* (1999); Pickar, *Dosage Calculations* (1999); and Remington: *The Science and Practice of Pharmacy*, 20th Edition, 2003, Gennaro, Ed., Lippincott, Williams & Wilkins). In sensitized cells, the therapeutically effective dose can often be lower than the conventional therapeutically effective dose for non-sensitized cells.


10

As used herein, the term "vascular prosthesis" refers to a prosthesis for the circulatory system of a mammal.


II. Compounds of the Present Invention

Macrocyclic lactones, their salts, prodrugs, tautomers and isomers will be referred to collectively as "macrocyclic lactones" in this invention.


The compounds of the present invention are macrocyclic lactone compounds of the following formula:




wherein $R^1, R^2, R^3, R^5, R^6, R^8, M^1, M^2, M^3, M^4, M^5, M^6$ and M^7 are each independently a member selected from the group consisting of H, C_{1-6} alkyl, OH and C_{1-6} hydroxy-alkyl; R^4, R^7 and R^9 are each independently selected from the group consisting of C_{1-6} alkoxy and OH; R^{10} is a member selected from the group consisting of H, —OH, —OP(O)Me₂,



—O—(CH₂)_n—OH and —O—(CH₂)_m—O—(CH₂)_o—CH₃, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L¹ and L² are independently selected from the group consisting of:




wherein each M⁸ is independently a member selected from the group consisting of C_{1-6} alkyl, OH and C_{1-6} hydroxy-alkyl; each of L² and L³ are independently selected from the group consisting of:




11


with the proviso that when R¹, R⁶, R⁸, M⁶ and M⁷ are Me, R³, R⁵, M¹, M², M³, M⁴ and M⁵ are H, R⁴, R⁷ and R⁹ are OMe, R¹⁰ and M⁸ are OH, L² and L³ are —CH=CH—, and L¹ and L⁴ are




R² is other than OH;
with the proviso that when R¹, R⁶, R⁸, M⁶ and M⁷ are Me, R², R³, R⁵, M¹, M², M³, M⁴ and M⁵ are H, R⁴, R⁷ and R⁹ are OMe, R¹⁰ and M⁸ are OH, L² and L³ are —CH=CH—, and L¹ and L⁴ are




R⁴ is other than OH;
with the proviso that when R¹, R⁶, R⁸, M⁶ and M⁷ are Me, R², R³, R⁵, M¹, M², M³, M⁴ and M⁵ are H, R⁴ and R⁷ are OMe, R¹⁰ and M⁸ are OH, L² and L³ are —CH=CH—, and L¹ and L⁴ are




R⁹ is other than OH;
with the proviso that when R¹, R⁶, R⁸, M⁶ and M⁷ are Me, R², R³, R⁵, M¹, M², M³, M⁴ and M⁵ are H, R⁴, R⁷ and R⁹ are OMe, M⁸ is OH, L² and L³ are —CH=CH—, and L¹ and L⁴ are




R¹⁰ is other than OH, —OP(O)Me₂,



—O—(CH₂)_m—OH and —O—(CH₂)_m—O—(CH₂)_nCH₃; and salts, hydrates, isomers, metabolites, N-oxides and prodrugs thereof.
In some embodiments, R¹⁰ is




In some other embodiments, R¹⁰ is



In other embodiments, R¹⁰ is —OP(O)Me₂.


12

In still other embodiments, R¹⁰ is



5


In another embodiment, R¹⁰ is



10


In a further embodiment, the compound is a compound of FIG. 2. In other embodiments, at least one of R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸ and R⁹ is OH. In still other embodiments, R⁴ is OH. In yet other embodiments, R¹, R⁶ and R⁸ are each methyl, R², R³ and R⁵ are each H, R⁴ and R¹⁰ are each OH, R⁷ and R⁹ are each OMe, M¹, M², M³, M⁴ and M⁵ are each H, M⁶ and M⁷ are each methyl, L¹ and L⁴ are each

20



and L² and L³ are each

25



30


The invention provides macrocyclic lactone compounds which are described in detail with Formula IA, IB, IC and ID.

In one embodiment, the composition contains macrocyclic lactones which include hydroxy, demethyl, hydroxydemethyl and epoxide macrocyclic lactones.

35

The structure of certain macrocyclic lactones with some potential sites for chemical modifications to provide compounds of the present invention is shown below.

40




60

wherein squares represent the demethylation positions; circles represent the hydroxylation positions; triangles represent the epoxidation positions; curved lines represent the N-oxidation position; dashed lines represent the position for ring-opening position; R¹⁰ is a member selected from the group consisting of —OH,

65


13



—OP(O)Me₂, —R^aOH, where R^a is alkyl, such as —(CH₂)₂ to (CH₂)₇, and —R^bOR^c, where R^b is C₂₋₆ alkylene and R^c is C₁₋₅ alkyl, such as 40-O-(ethoxyethyl) rapamycin.

In some embodiments, the compounds of the present invention include certain demethyl macrocyclic lactones, such as 16-O-demethyl macrocyclic lactone, 39-O-demethyl macrocyclic lactone, 27-O-demethyl macrocyclic lactone, 16, 27-bis-O-demethyl macrocyclic lactone, 27, 39-bis-O-demethyl macrocyclic lactone, 16, 39-bis-O-demethyl macrocyclic lactone, individually or in combination with each other, as shown in Formula IA.

Formula IA



wherein

Each of R⁴, R⁷ and R⁹ are selected from the group of consisting of —OCH₃ and —OH.

R⁴ and R⁷ are both, independently, selected from the group of consisting of —OH and —OCH₃.

R⁷ and R⁹ are both, independently, selected from the group of consisting of —OH and —OCH₃.

R⁴ and R⁹ are both, independently, selected from the group of consisting of —OH and —OCH₃.


R⁴, R⁷ and R⁹ are each, independently, selected from the group of consisting of —OH and —OCH₃.

And wherein R¹⁰ is as described above.

In another embodiment, the compounds of the present invention includes compositions of hydroxyl macrocyclic lactone, such as 11-hydroxyl macrocyclic lactone, 12-hydroxyl macrocyclic lactone, 14-hydroxyl macrocyclic lactone, 24-hydroxyl macrocyclic lactone, 25-hydroxyl macrocyclic lactone, 25-methyl alcohol macrocyclic lactone, 31-methyl alcohol macrocyclic lactone, 35-methyl alcohol macrocyclic lactone, 13-methyl alcohol macrocyclic lactone, individually or in combination with each other, as shown in Formula IB.


14

Formula IB



wherein


Each of R¹, R⁶, R⁸, M⁶, M⁷, M⁸ and M^{8a} are selected from the group of consisting of —CH₃, —CH₂OH and —OH. Each of R², R³, R⁵, M¹, M², M³, M⁴ and M⁵ are selected from the group of consisting of —H and —OH. R⁹ is selected from the group of consisting of —OH and —OCH₃. L₂ is selected from the group of consisting of



And wherein R¹⁰ is as described above.



In another embodiment, the compounds of the present invention include compositions of epoxide macrocyclic lactone, such as 19, 20-21, 22-29, 30 tris epoxide macrocyclic lactone, 17, 18-19, 20-21, 22 tris epoxide macrocyclic lactone and 17, 18-29, 30 bis epoxide macrocyclic lactone, as shown in Formula IC.

Formula IC



15

-continued






And wherein R¹⁰ is as described above.

Formula ID

In another embodiment, the compounds of the present invention include compositions of N-oxidized macrocyclic lactone, 11-hydroxyl with 10,14 ring opening macrocyclic lactone, seco-macrocyclic lactone (with 1, 34 ring opened), as shown in Formula ID.


16



Wherein each of R¹, R⁶, R⁸, M⁶, M⁷, M⁸ and M^{8a} are independently selected from the group of consisting of —CH₃, —OH and C₁₋₆ hydroxyalkyl. Each of R², R³, R⁵, M¹, M², M³, M⁴ and M⁵ are independently selected from the group of consisting of —H and —OH. R⁴, R⁷, R⁹ are indepen-

17

dently selected from the group of consisting of —OH and —OCH₃. L² is selected from the group of consisting of



In another embodiment, the compounds of the present invention are a combination of Formula IA and Formula IB, including composition of demethylhydroxy macrocyclic lactone such as 14-hydroxy-39-O-demethyl macrocyclic lactone, 16,39-bis-O-demethyl-24-hydroxy macrocyclic lactone, 16,27-bis-O-demethyl-24-hydroxy macrocyclic lactone, 27,39-bis-O-demethyl-24-hydroxy macrocyclic lactone individually or in combination with each other.

In another embodiment, the compounds of the present invention are a combination of Formula IA and Formula IC, including composition of epoxide demethyl macrocyclic lactone such as 17,18-19,20-bis-epoxide-16-O-demethyl mac-

18

rocyclic lactone, 17,18-29,30-bis-epoxide-16-O -demethyl macrocyclic lactone, individually or in combination with each other.

In yet another embodiment, the compounds of the present invention are a combination of Formula IA, Formula IB and Formula IC, including composition of epoxide demethylhydroxyl macrocyclic lactone such as

17,18-19,20-bis-epoxide-16-O-demethyl-24-hydroxymacrocyclic lactone, 17,18-29,30-bis-epoxide-16-O-demethyl-24-hydroxymacrocyclic lactone, individually or in combination with each other.

This invention also covers the compositions of salts, hydrates, isomers, tautomers, metabolites, N-oxides and prodrugs of compounds of the present invention of Formula IA, IB, IC and ID.





Structures of preferred embodiments (A,B,C, . . . AA,AB, AC, . . . FB,FC,FD) amongst compounds of the present invention of Formula IA, IB, IC and ID, and their combinations, are shown in Table 1, along with some in FIG. 2A-2FV.  and  include both stereocenter:  and 

TABLE 1

Table of preferred compounds.

	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷	R ⁸	R ⁹	R ¹⁰	M ¹	M ²	M ³	M ⁴	M ⁵	M ⁶	M ⁷	L ¹	L ²	L ³	L ⁴
*	Me	H	H	OMe	H	Me	OMe	Me	OMe	OH	H	H	H	H	H	Me	Me				
A																					
B									OH												
C	OH						OH														
D		OH																			
E			OH																		
F				OH																	
G					OH																
H						OH															
I																					




TABLE 1-continued

Table of preferred compounds.

	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷	R ⁸	R ⁹	R ¹⁰	M ¹	M ²	M ³	M ⁴	M ⁵	M ⁶	M ⁷	L ¹	L ²	L ³	L ⁴	
J																						
K							OH															
L	OH																					
M		OH																				
N																						





TABLE 1-continued

Table of preferred compounds.

	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷	R ⁸	R ⁹	R ¹⁰	M ¹	M ²	M ³	M ⁴	M ⁵	M ⁶	M ⁷	L ¹	L ²	L ³	L ⁴	
S	OH																					
T		OH																				
U					OH																	
V																						
W																						
X																						
Y																						
Z																						






TABLE 1-continued

Table of preferred compounds.

	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷	R ⁸	R ⁹	R ¹⁰	M ¹	M ²	M ³	M ⁴	M ⁵	M ⁶	M ⁷	L ¹	L ²	L ³	L ⁴	L ⁵	
AA		OH																					
AB					OH					-OP(O)Me ₂													
AC						OH				-OP(O)Me ₂													
AD							OH		OH	-OP(O)Me ₂													
AE										HO													
AF										HO													
AG	OH									HO													
AH										HO													
AI									OH	HO													
AJ										HO													




TABLE 1-continued

Table of preferred compounds.

	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷	R ⁸	R ⁹	R ¹⁰	M ¹	M ²	M ³	M ⁴	M ⁵	M ⁶	M ⁷	L ¹	L ²	L ³	L ⁴	
AU	OH																					
AV	OH																					
AW	OH	OH																				
AX	OH	OH																				





TABLE 1-continued

Table of preferred compounds.

	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷	R ⁸	R ⁹	R ¹⁰	M ¹	M ²	M ³	M ⁴	M ⁵	M ⁶	M ⁷	L ¹	L ²	L ³	L ⁴
AY																					
AZ																					
BA																					
BB																					
BC																					
BD																					
BE																					
BF																					
BG																					
BH																					

TABLE 1-continued

Table of preferred compounds.

	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷	R ⁸	R ⁹	R ¹⁰	M ¹	M ²	M ³	M ⁴	M ⁵	M ⁶	M ⁷	L ¹	L ²	L ³	L ⁴	
BI																						
BJ						CH ₂ OH																
BK					CH ₂ OH																	
BL																						
BM																						
BN																						
BO																						












TABLE 1-continued

Table of preferred compounds.

	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷	R ⁸	R ⁹	R ¹⁰	M ¹	M ²	M ³	M ⁴	M ⁵	M ⁶	M ⁷	L ¹	L ²	L ³	L ⁴	
BP																						
BQ																						
BR	CH ₂ OH																					
BS																						
BT																						



CH₂OH


OH

OH


TABLE 1-continued

Table of preferred compounds.

	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷	R ⁸	R ⁹	R ¹⁰	M ¹	M ²	M ³	M ⁴	M ⁵	M ⁶	M ⁷	L ¹	L ²	L ³	L ⁴	
BU						CH ₂ OH																
BV																						
BW																						
BX								CH ₂ OH														
BY																						



CH₂OH



CH₂OH

TABLE 1-continued

Table of preferred compounds.

	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷	R ⁸	R ⁹	R ¹⁰	M ¹	M ²	M ³	M ⁴	M ⁵	M ⁶	M ⁷	L ¹	L ²	L ³	L ⁴	
BZ																						
CA																						
CB																						
CC																						









TABLE 1-continued

Table of preferred compounds.

	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷	R ⁸	R ⁹	R ¹⁰	M ¹	M ²	M ³	M ⁴	M ⁵	M ⁶	M ⁷	L ¹	L ²	L ³	L ⁴	
CD	CH ₂ OH																					
CE																						
CF																						
CG																						




CH₂OH

CH₂OH

TABLE 1-continued

Table of preferred compounds.

	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷	R ⁸	R ⁹	R ¹⁰	M ¹	M ²	M ³	M ⁴	M ⁵	M ⁶	M ⁷	L ¹	L ²	L ³	L ⁴	
CH																						
CI																						CH ₂ OH
CJ								CH ₂ OH														
CK																						
CL																						
CM																						
CN																						
CO																						
CP																						CH ₂ OH









TABLE 1-continued

Table of preferred compounds.

	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷	R ⁸	R ⁹	R ¹⁰	M ¹	M ²	M ³	M ⁴	M ⁵	M ⁶	M ⁷	L ¹	L ²	L ³	L ⁴	
CQ																						
CR																						
CS					CH ₃ OH																	
CT																						
CU																						
CV																						
CW																						
CX																						
CY																						






TABLE 1-continued

Table of preferred compounds.

	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷	R ⁸	R ⁹	R ¹⁰	M ¹	M ²	M ³	M ⁴	M ⁵	M ⁶	M ⁷	L ¹	L ²	L ³	L ⁴	
CZ										HO-CH ₂ -CH ₂ -CH ₂ -CH ₂ -O-CH ₃												
DA										HO-CH ₂ -CH ₂ -CH ₂ -CH ₂ -O-CH ₃												
DB	CH ₂ OH									HO-CH ₂ -CH ₂ -CH ₂ -CH ₂ -O-CH ₃												
DC										HO-CH ₂ -CH ₂ -CH ₂ -CH ₂ -O-CH ₃												
DD										HO-CH ₂ -CH ₂ -CH ₂ -CH ₂ -O-CH ₃												
DE					CH ₂ OH					HO-CH ₂ -CH ₂ -CH ₂ -CH ₂ -O-CH ₃												



CH₂OH

CH₂OH

TABLE 1-continued

Table of preferred compounds.

	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷	R ⁸	R ⁹	R ¹⁰	M ¹	M ²	M ³	M ⁴	M ⁵	M ⁶	M ⁷	L ¹	L ²	L ³	L ⁴		
DF																							
DG																							CH ₂ OH
DH								CH ₂ OH															
DI																							
DJ																							
DK																							
DL																							
DM																							





TABLE 1-continued

Table of preferred compounds.

	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷	R ⁸	R ⁹	R ¹⁰	M ¹	M ²	M ³	M ⁴	M ⁵	M ⁶	M ⁷	L ¹	L ²	L ³	L ⁴	
DN	CH ₂ OH										Me-CH ₂ -O-CH ₂ -O-Me											
DO											Me-CH ₂ -O-CH ₂ -O-Me											
DP																	CH ₂ OH					
DQ					CH ₂ OH																	
DR																						
DS											Me-CH ₂ -O-CH ₂ -O-Me											




TABLE 1-continued

Table of preferred compounds.

	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷	R ⁸	R ⁹	R ¹⁰	M ¹	M ²	M ³	M ⁴	M ⁵	M ⁶	M ⁷	L ¹	L ²	L ³	L ⁴	
DT								CH ₂ OH														
DU																						
DV				OH																		
DW									OH													
DX										OH												




TABLE 1-continued

Table of preferred compounds.


















	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷	R ⁸	R ⁹	R ¹⁰	M ¹	M ²	M ³	M ⁴	M ⁵	M ⁶	M ⁷	L ¹	L ²	L ³	L ⁴
DY				OH																	
DZ																					
EA				OH																	
EB							OH														

TABLE 1-continued

Table of preferred compounds.







































	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷	R ⁸	R ⁹	R ¹⁰	M ¹	M ²	M ³	M ⁴	M ⁵	M ⁶	M ⁷	L ¹	L ²	L ³	L ⁴
EC	OH																				
ED		OH					OH														
EE																					
EF																					

TABLE 1-continued

Table of preferred compounds.

	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷	R ⁸	R ⁹	R ¹⁰	M ¹	M ²	M ³	M ⁴	M ⁵	M ⁶	M ⁷	L ¹	L ²	L ³	L ⁴	
EO	OH																					
EP		OH		OH			OH															
EQ																						
ER																						



OH —OP(O)Me₂

—OP(O)Me₂

—OP(O)Me₂

Me—O—O—Me

TABLE 1-continued

Table of preferred compounds.

	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷	R ⁸	R ⁹	R ¹⁰	M ¹	M ²	M ³	M ⁴	M ⁵	M ⁶	M ⁷	L ¹	L ²	L ³	L ⁴
ES		OH								Me-CH ₂ -O-CH ₂ -O-CH ₂ -Me								Me-CH ₂ -O-CH ₂ -O-CH ₂ -Me	Me-CH ₂ -O-CH ₂ -O-CH ₂ -Me	Me-CH ₂ -O-CH ₂ -O-CH ₂ -Me	Me-CH ₂ -O-CH ₂ -O-CH ₂ -Me
ET				OH						Me-CH ₂ -O-CH ₂ -O-CH ₂ -Me								Me-CH ₂ -O-CH ₂ -O-CH ₂ -Me	Me-CH ₂ -O-CH ₂ -O-CH ₂ -Me	Me-CH ₂ -O-CH ₂ -O-CH ₂ -Me	Me-CH ₂ -O-CH ₂ -O-CH ₂ -Me
EU					OH					Me-CH ₂ -O-CH ₂ -O-CH ₂ -Me								Me-CH ₂ -O-CH ₂ -O-CH ₂ -Me	Me-CH ₂ -O-CH ₂ -O-CH ₂ -Me	Me-CH ₂ -O-CH ₂ -O-CH ₂ -Me	Me-CH ₂ -O-CH ₂ -O-CH ₂ -Me
EV				OH						Me-CH ₂ -O-CH ₂ -O-CH ₂ -Me								Me-CH ₂ -O-CH ₂ -O-CH ₂ -Me	Me-CH ₂ -O-CH ₂ -O-CH ₂ -Me	Me-CH ₂ -O-CH ₂ -O-CH ₂ -Me	Me-CH ₂ -O-CH ₂ -O-CH ₂ -Me

TABLE 1-continued

Table of preferred compounds.

	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷	R ⁸	R ⁹	R ¹⁰	M ¹	M ²	M ³	M ⁴	M ⁵	M ⁶	M ⁷	L ¹	L ²	L ³	L ⁴	
EW																						
EX				OH																		
EY					OH																	
EZ						OH																


TABLE 1-continued

Table of preferred compounds.

	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷	R ⁸	R ⁹	R ¹⁰	M ¹	M ²	M ³	M ⁴	M ⁵	M ⁶	M ⁷	L ¹	L ²	L ³	L ⁴
EA	OH	OH	OH	OH	OH	OH	OH	OH	OH	HO-CH ₂ -CH ₂ -CH ₂ -O-Me								2-methyl-oxirane	2-methyl-oxirane	2-methyl-oxirane	2-methyl-oxirane
FB										HO-CH ₂ -CH ₂ -CH ₂ -O-Me								2-methyl-oxirane	2-methyl-oxirane	2-methyl-oxirane	2-methyl-oxirane
FC										—OP(O)Me ₂											
FD										Me-CH ₂ -O-CH ₂ -CH ₂ -O-Me											

*Rapamycin. All —OH substitutions represent a mixture of both the R and the S isomer.

In some embodiments, the compound of the present invention has the following structure:



This invention covers compounds in which the stereochemistry of the 16-position is racemic (R,S) as well as the individual R and S stereoisomers at the 16-position and all other isomers of the compound.

The invention covers compounds with different polymorphic forms. This includes 16-O-demethyl macrocyclic lactone having different polymorphic forms. For example, different polymorphs form of 16-O-demethyl macrocyclic lactone are obtained from using dichloromethylene and from using a mixture of methanol and water

There have been different numbering schemes proposed for macrocyclic lactones. To avoid confusion, when specific macrocyclic lactones are named herein, the names are given with reference to macrocyclic lactone using the numbering scheme of the above chemical formula. This invention also covers all the macrocyclic lactones which have different name due to a different numbering scheme if the same functional group exists in the same location within the chemical structure. For example, 39-O-demethyl macrocyclic lactone is the same compound as 41-O-demethyl macrocyclic lactone and 16-O-demethyl macrocyclic lactone is the same compound as 7-O-demethyl macrocyclic lactone.

The compounds of the present invention can be prepared by a variety of methods. In some embodiments, the compounds of the present invention are synthesized biologically by genetically modifying the strains of organisms to produce the compounds of the present invention or by other means.

In another embodiment the compounds of the present invention are prepared using chemical synthesis. Chemical synthesis of the compounds of the present invention can utilize the 17-18, 19-20, 21-22 triene structure in macrocyclic lactones, which facilitates the acid catalyzed nucleophilic substitution of the C16 methoxy group and allows the introduction of a number of different substitutions and allows the selective manipulation of macrocyclic lactone effector domain. The C16 methoxy group in macrocyclic lactones is manipulated towards acidic reagents to produce the compounds of the present invention. For example, replacement of C16 methoxy groups with different nucleophiles such as alcohols, thiols and electron rich aromatic groups can be

accomplished. This method of synthesis can be performed without protection and deprotection steps.

The method of synthesis of using acidic reagents with compounds having triene functional groups can be applied to other compounds having triene functional groups to synthesize corresponding compound analogues providing a method of synthesis without protection and deprotection steps

In some embodiments, the present invention provides a method of making a compound of the present invention, the method comprising contacting a macrocyclic lactone with an acid to replace an alkoxy group with a nucleophile, thereby making a compound of the present invention. In some other embodiments, the macrocyclic lactone is rapamycin. In other embodiments, the nucleophile is a member selected from the group consisting of —OH, —SH and electron rich aromatic groups. One of skill in the art will appreciate that other methods are useful for preparing the compounds of the present invention.

Synthesis of demethyl macrocyclic lactone is provided in FIG. 14 using 16-O-demethyl macrocyclic lactone as an example. Synthesis of hydroxy macrocyclic lactone is provided in FIG. 15 using 19, 20 bis-hydroxy macrocyclic lactone as an example. Synthesis of epoxide macrocyclic lactone is provided in FIG. 16 using 17,18-29,30-bis epoxide macrocyclic lactone as an example.

In another embodiment, the present invention provides a method of making a compound of the present invention, the method comprising contacting a macrocyclic lactone with a suitable agent such as a peracid or peroxide, to modify an alkene group to an epoxide, thereby making a compound of the present invention. Peracids useful in the methods of the present invention include, but are not limited to, peroxy-carboxylic acids of the formula R—C(O)—OOH, where the R group can be groups such as H, alkyl, alkene or aryl. In some embodiments, the peracid can be peroxy-acetic acid or meta-chloro-peroxybenzoic acid (MCPBA). Peroxides useful in the methods of the present invention include, but are not limited to, hydrogen peroxide. One of skill in the art will appreciate that other epoxidation reagents are useful in the present invention.

The compounds of the present invention are optionally deuterated.

In some embodiments, the present invention provides compounds of the present invention which have a similar potency to the corresponding parent macrocyclic lactone. In another embodiment, the present invention provides compounds of the present invention which are less potent than the corresponding parent macrocyclic lactone in order to improve the safety profile of the compounds.

III. Delivery of the Compounds of the Present Invention

The compounds of the present invention can be administered in any appropriate manner. In some embodiments, the compounds are administered orally, intramuscularly, intraperitoneally, subcutaneously, pulmonarily, mucosally, transdermally, intravascularly, intraocularly or intravitreally through the eye, and others. In other embodiments, the compounds are administered site specifically through temporary or permanent drug delivery means such as an implant or a combination of systemic and site specific means. Examples include, but are not limited to catheter, stent, vascular wrap, pump, shunt or other temporary or permanent drug delivery means.

A. Device

In some embodiments, the present invention provides a device for intracorporeal use, the device comprising a vascular prosthesis; and at least one source of a compound of the present invention.

In other embodiments, the present invention provides a device configured to release the compound to a body lumen or organ within an intracorporeal body to inhibit cell proliferation or cell migration. In a further embodiment, the device is configured to release the compound to a body lumen or organ within an intracorporeal body to inhibit smooth muscle cell proliferation or neo-vascularization.

In another embodiment of the present invention the drug delivery means is a device such as an implant including graft implants, vascular implants, non-vascular implants, implantable luminal prostheses, wound closure implants, drug delivery implants, sutures, biologic delivery implants, urinary tract implants, inter-uterine implants, organ implants, ophthalmic implants, bone implants including bone plates, bone screws, dental implants, spinal disks, or the like.

When the device is configured for treatment of ophthalmic conditions or diseases, the implant of the present invention can be implanted intraocularly or intravitreally by an intervention procedure. Such implants can be non-biodegradable, biodegradable, removable or permanent. In other embodiments, implants can be placed in the duct, such as the tear duct. In still other embodiments, implants can be placed adjacent to the ocular body, or intraocularly, adjacent to the vitreal body or intravitreally. One of skill in the art will appreciate that other locations are useful in the present invention.

The implant typically allows for one or more of the following: support, contain, hold together, affix, plug, close, maintain, deliver drug, deliver biologics—to a body lumen, organ, vessel, conduit, muscle, tissue mass or bone for the prevention or treatment of disease conditions, such as for example hyper-proliferative diseases, restenosis, cardiovascular disease, inflammation, wound healing, cancer, aneurysm, diabetic disease, abdominal aortic aneurysm, hyper-calcemia, or others.

The implant of the present invention can be formed of metal, metal alloy, polymer, ceramic, semi-metal, nanocomposites or combination thereof. For example, an implant can be made from metal such as tantalum, iron, magnesium, molybdenum or others; from a degradable or non degradable metal alloy such as 316L stainless steel, carbon steel, magnesium alloy, Ni—Ti, Co—Cr such as L605, MP35 or other; from a polymer that is degradable or non-degradable such as poly lactic acid, poly glycolic acid, poly esters, polyamide, copolymers or others or blends of polymers; combination of metals and metals or metal alloys such as implant made from combination of layers of stainless steel and tantalum or others; nanocomposites such as nano carbon fibers or nano carbon tubules or others.

In another embodiment, the present invention provides a device wherein the implant is a vascular prosthesis. In some embodiments, the vascular prosthesis comprises an expandable structure. In other embodiments, the vascular prosthesis comprises a stent, graft, or a scaffold formed at least in part from an open lattice. In still other embodiments, the vascular prosthesis is a stent.

In another embodiment, the compounds of the present invention can be applied adjacent to the surface of the implant. For example the compounds of the present invention can be incorporated within the implant, contained within a coating, or carried on the implant.

In some embodiments, the present invention provides a device comprising a vascular prosthesis wherein the vascular prosthesis has a luminal and a tissue facing surface, and wherein the compound is associated with at least one of the luminal or tissue facing surfaces.

In a further embodiment, the compounds of the present invention are applied on all implant surfaces. In another

embodiment, the compounds of the present invention are applied only to the abluminal or luminal surface. In yet another embodiment, the compounds of the present invention are applied only to high stress or low stress areas.

In another embodiment, the compounds of the present invention are contained within an erodible or non-erodible filament or filaments that are adjacent to the implant.

An example of a stent configuration for carrying a compound of the present invention is illustrated in FIG. 3 in a contracted state. The stent body is formed of multiple rings **110**. The rings are formed of crowns **120** and struts **130** in a generally expandable undulating configurations such as, zig-zag, sawtooth, sinusoidal wave or other. The body is joined by links or connectors **140**. It is understood that the connectors may be of any length or shape, or may not be needed if the crowns are directly attached to each other. The stent has a typical contracted state diameter of between 0.25-4 mm, or more preferably between 0.7 to 1.5 mm, and a length of between 5 and 100 mm. In its expanded state, the stent diameter is typically at least twice and up to 10 times or more than that of the stent in its contracted state. Thus, a stent with a contracted diameter of between 0.7 to 1.5 mm may expand radially to 2 to 10mm or more.

Drug eluting stents with potent macrocyclic lactone compounds such as rapamycin (Cypher™) have resulted in late lumen loss in the range of approximately 0.01 mm to 0.2 mm at approximately 4 months to 12 months angiographic follow up. The late lumen loss with bare metal stents have ranged from approximately 0.70 mm to 1.2 mm for the same time period. Lower late lumen loss typically decreased the percent stenosis. However, significantly lower late lumen loss with drug eluting stents as compared to bare metal stents in some cases results in inadequate tissue coverage of the stent surface which potentially may increase incidence of late stent thrombosis.

In a preferred embodiment, the late lumen loss for stent carrying compounds of the present invention after approximately 4 to 12 months after implantation is greater than the late lumen loss for stent carrying the corresponding parent macrocyclic lactone by 0.05 mm to 0.6 mm, preferably by 0.1 mm to 0.4 mm, more preferably by 0.15 to 0.3 mm. For example, late lumen loss after implantation ranges from 0.01 mm to 0.6 mm, preferably from 0.1 mm to 0.5 mm and most preferably from 0.2 mm to 0.4 mm. In another embodiment, the present invention provides late lumen loss for stent carrying compounds of the present invention similar to a stent carrying the corresponding parent macrocyclic lactone. In another preferred embodiment, the present invention provides late lumen loss for stent carrying compounds of the present invention being higher than for a stent carrying the corresponding parent macrocyclic lactone. Higher late lumen can provide increased tissue coverage of the stent which can improve safety of the stent.

In another preferred embodiment, the percent stenosis approximately 4 to 12 months after implantation for a stent carrying compounds of the present invention is greater by 1 to 30 percentage than the percent stenosis for a stent carrying the corresponding parent macrocyclic lactone, preferably from 3 to 20 percentage, more preferably from 5 to 15 percentage. In yet another preferred embodiment, the present invention provides percent stenosis for a stent carrying compounds of the present invention similar to a stent carrying the corresponding parent macrocyclic lactone. In another preferred embodiment, the present invention provides percent stenosis for a stent carrying compounds of the present invention higher than a stent carrying the corresponding parent macrocyclic lactone. In another preferred embodiment, the percent stenosis

for a stent carrying compounds of the present invention is higher than a stent carrying the corresponding parent macrocyclic lactone but lower than the bare metal stent. Higher stenosis can provide increased tissue coverage of the stent which can improve safety of the stent.

In some embodiments, the present invention provides a device wherein the amount of compounds of the present invention on the implant is less than about 1 g/cm². In other embodiments, the amount of compounds on the implant can range from about 1 nanogram/cm² to about 1000 microgram/cm², preferably from about 1 microgram/cm² to about 500 microgram/cm², more preferably from about 10 microgram/cm² to about 400 microgram/cm². In still other embodiments, the amount of compound on the implant is less than about 1 mg. In yet other embodiments, the amount of compound on the implant is from about 1 µg to about 50 mg, preferably from about 100 µg to about 10 mg, more preferably from about 200 µg to about 500 µg.

In a further embodiment, the present invention provides a device wherein the concentration of the compound of the present invention in the tissue adjacent to the implant is from about 0.001 ng/gm tissue to about 1000 µg/gm tissue, preferably from about 1 ng/gm tissue to about 500 µg/gm tissue, more preferably from about 100 ng/gm tissue to about 100 µg/gm tissue.

In another embodiment, the compounds of the present invention can be released from the implant over a period ranging from less than 5 minutes to 2 years, preferably from 3 days to 6 months, more preferably from 1 week to 3 months. In other embodiments, the compounds of the present invention can be released from the implant over a period greater than 1 day, preferably greater than 2 weeks, more preferably greater than 1 month. In another embodiment, the compounds of the present invention can require greater than 2 years to be fully released from the stent. In some embodiments, the amount of compound released over the given time period is at least 25%. In other embodiments, the amount of compound released is at least 50%. In still other embodiments, the amount of compound released is at least 75%. In yet other embodiments, the amount of compound released can be at least 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%.

In a further embodiment, the present invention provides a device wherein at least 75% of the compound is released from the device in a period from about 1 day to about 2 years. In another embodiment, at least 90% of the compound is released from the device in a period from about 3 day to about 6 months. In still another embodiment, at least 90% of the compound is released from the device in a period from about 1 week to about 3 months.

When the compounds of the present invention are administered via injection or eye drop through an intraocular or intravitreal body, the concentration of compound alone or within the polymer matrix, solvent or carrier can vary from 1 µg/ml to 5 mg/ml, and preferably from 5 µg/ml to 30 µg/ml. Following administration, the concentration of the compound of the present invention in the tissue adjacent to the site of administration can be from about 0.1 nM to 500 µM, preferably from about 1 nM to 100 µM, more preferably from about 10 nM to 10 µM. One of skill in the art will appreciate that other concentrations of the compounds of the present invention are useful.

The compounds of the present invention can be released from the implant via any means known in the art. In some embodiments, the implant releases the compound through active or passive means. In other embodiments, the implant releases the compound through osmotic pressure or diffusion.

One of skill in the art will appreciate that other means of releasing the compound from the implant are useful in the present invention.

In some embodiments, the present invention provides a device that further includes a therapeutic agent, such as those described below. In some other embodiments, the therapeutic agent is released prior to, concurrent with, or subsequent to the release of the compound. In other embodiments, the compound is released from a first source and the therapeutic agent is released from a second source. In still other embodiments, the compound and the therapeutic agent are released from a single source.

B. Administration


The compounds of the present invention can be administered systemically on a daily, intermittent or one-time dose basis. The daily systemic dose can range from 0.1 mg to 20 mg preferably 0.5 mg to 10 mg, most preferably from 1 mg to 5 mg per day. One of skill in the art will appreciate that other doses are also useful in the present invention.

The compounds of the present invention can be released from the implant at rates ranging from about 1 nanogram/cm²/day to about 1000 microgram/cm²/day, preferably from about 1 microgram/cm²/day to about 200 microgram/cm²/day, more preferably from about 5 microgram/cm²/day to about 100 microgram/cm²/day.

When the device of the present invention is configured for treatment of ophthalmic conditions or diseases, the compounds of the present invention can be administered through the eye as an eye drop or an injection on a daily, intermittent or one time dose basis. The dose can range from 0.1 µg to 30 mg, preferably from 10 µg to 10 mg, most preferably from 100 µg to 1 mg per day. One of skill in the art will appreciate that other doses are also useful in the present invention.

C. Pharmaceutical Formulations


In some embodiments, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula:



wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, M¹, M², M³, M⁴, M⁵, M⁶, M⁷, L¹, L², L³ and L⁴ are as described above; and salts, hydrates, isomers, metabolites, N-oxides and prodrugs thereof.


In some other embodiments, the present invention provides a pharmaceutical composition including a pharmaceutically acceptable excipient and a compound of the formula:

79




wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , R^9 , R^{10} , M^1 , M^2 , M^3 , M^4 , M^5 , M^6 , M^7 , L^1 , L^2 , L^3 and L^4 are as described above; and salts, hydrates, isomers, metabolites, N-oxides and prodrugs thereof.

In still other embodiments, the present invention provides a pharmaceutical composition including a pharmaceutically acceptable excipient and a compound of the formula:



wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , R^9 , R^{10} , M^1 , M^2 , M^3 , M^4 , M^5 , M^6 , M^7 , L^1 , L^2 , L^3 and L^4 are as described above; and salts, hydrates, isomers, metabolites, N-oxides and prodrugs thereof.


In another embodiment, the pharmaceutical composition includes a compound of FIG. 2. In other embodiments, R^1 , R^6 and R^8 are each methyl, R^2 , R^3 and R^5 are each H, R^4 and R^{10} are each OH, R^7 and R^9 are each OMe, M^1 , M^2 , M^3 , M^4 and M^5 are each H, M^6 and M^7 are each methyl, L^1 and L^4 are each



80

and L^2 and L^3 are each

5



10

In some embodiments, the present invention provides a pharmaceutical composition wherein the pharmaceutically acceptable excipient is a member selected from the group consisting of a polymer, a solvent, an antioxidant, a binder, a filler, a disintegrant, a lubricant, a coating, a sweetener, a flavor, a stabilizer, a colorant, a metal, a ceramic and a semi-metal. In other embodiments, the pharmaceutically acceptable excipient is a polymer.

15

The active ingredients of the present invention may be mixed with pharmaceutically acceptable carriers, diluents, adjuvants, excipients, or vehicles, such as preserving agents, fillers, polymers, disintegrating agents, glidants, wetting agents, emulsifying agents, suspending agents, sweetening agents, flavoring agents, perfuming agents, lubricating agents, acidifying agents, and dispensing agents, depending on the nature of the mode of administration and dosage forms.

20

Such ingredients, including pharmaceutically acceptable carriers and excipients that may be used to formulate oral dosage forms, are described in the Handbook of Pharmaceutical Excipients, American Pharmaceutical Association (1986), incorporated herein by reference in its entirety. Examples of pharmaceutically acceptable carriers include water, ethanol, polyols, vegetable oils, fats, waxes polymers, including gel forming and non-gel forming polymers, and suitable mixtures thereof. Examples of excipients include starch, pre-gelatinized starch, Avicel, lactose, milk sugar, sodium citrate, calcium carbonate, dicalcium phosphate, and lake blend. Examples of disintegrating agents include starch, alginic acids, and certain complex silicates. Examples of lubricants include magnesium stearate, sodium lauryl sulphate, talc, as well as high molecular weight polyethylene glycols. One of skill in the art will appreciate that other different excipients can be used in formulations according to the present invention and the list provided herein is not exhaustive.

35

Suitable nondegradable or slow degrading polymer coatings include, but are not limited to, polyacrylamide, poly-N-vinylpyrrolidone, polydimethyl acrylamide, polymers and copolymers of 2-acrylamido-2-methyl-propanesulfonic acid, acrylic acid and methacrylic acid, polyurethane, polyethylenes imine, ethylene vinyl alcohol copolymer, silicone, C-flex, nylons, polyamide, polyimide, polytetrafluoroethylene (PTFE), parylene, parylast, poly (methyl methacrylate), poly(n-butyl methacrylate), poly (butyl methacrylate) copolymer or blended with poly(ethylene vinyl acetate), poly (methyl methacrylate), poly (2-hydroxy ethyl methacrylate), poly(ethylene glycol methacrylates), poly(vinyl chloride), poly(dimethyl siloxane), poly(ethylene vinyl acetate), polycarbonate, polyacrylamide gels, and the like, including other synthetic or natural polymeric substances; mixtures, copolymers, or combinations thereof.

55

Suitable biodegradable polymer coatings include, but are not limited to, poly(lactic acid), polylactates, poly(glycolic acid), polyglycolates and copolymers, poly dioxanone, poly (ethyl glutamate), poly(hydroxybutyrate), polyhydroxyvalerate and copolymers, polycaprolactone, polyanhydride, poly (ortho esters); poly(ether esters), poly ethylene glycols, poly (ethylene oxide), poly (trimethyl carbonate), polyethylenecarbonate, copolymers of poly(ethylenecarbonate) and poly(trimethyl carbonate), poly(propylene carbonate), poly(iminocarbonates), starch based polymers, cellulose acetate butyrate, polyester amides, polyester amines, polycyanoacrylates, polyphosphazenes, Poly N-vinyl-2-pyrrolidone, poly maleic anhydride, hyaluronic acid (hyaluronate),

65

chondroitin sulfate, dermatan sulfate, carboxymethylcellulose, heparin sulfate, keratan sulfate, carboxymethylhydroxypropylcellulose, carboxymethylhydroxyethylcellulose, cellulose sulfate, cellulose phosphate, carboxymethylguar, carboxymethylhydroxypropylguar, carboxymethylhydroxyethylguar, xanthan gum, carrageenan, anionic polysaccharides, anionic proteins and polypeptides, quaternary ammonium compounds including stearyl ammonium chloride and benzyl ammonium chloride, copolymers and other aliphatic polyesters, or suitable copolymers thereof including copolymers of poly(L-lactic acid) and poly(ϵ -caprolactone); mixtures, copolymers, ionic polymers, or combinations thereof.

Suitable natural coatings include: fibrin, albumin, collagen, gelatin, glycosaminoglycans, oligosaccharides and poly saccharides, chondroitin, chondroitin sulphates, hyposyapatite, phospholipids, phosphorylcholine, glycolipids, fatty acids, proteins, cellulose, and mixtures, copolymers, or combinations thereof.

Suitable non polymeric coatings include metallic coatings such as tungsten, magnesium, cobalt, zinc, iron, bismuth, tantalum, gold, platinum, stainless steel such as 316L, 304, titanium alloys; ceramics coatings such as silicon oxide; semi-metals such as carbon, nanoporous coatings; or combination thereof.

In some embodiments, the pharmaceutically acceptable excipient is a polymer is selected from the group consisting of polyurethane, polyethylene imine, ethylene vinyl alcohol copolymer, silicone, C-flex, nylons, polyamide, polyimide, polytetrafluoroethylene (PTFE), parylene, parylast, poly(methacrylate), poly(vinyl chloride), poly(dimethyl siloxane), poly(ethylene vinyl acetate), polycarbonate, polyacrylamide gels, poly(methyl methacrylate), poly(n-butyl methacrylate), poly(butyl methacrylate) copolymer or blended with poly(ethylene vinyl acetate), poly(methyl methacrylate), poly(2-hydroxy ethyl methacrylate), poly(ethylene glycol methacrylates), poly(ethylene carbonate), Poly L lactide-glycolide copolymer, poly L lactide-trimethylene carbonate copolymer and Poly L-lactide. In a further embodiment, the polymer is poly(n-butylmethacrylate).

In a further embodiment, the present invention provides a composition wherein the compound is present in an amount of at least 10% (w/w) in a mixture of the compound and the polymer. In another embodiment, the compound is present in an amount of at least 20, 25, 30, 40, 50, 55, 60, 70, 75, 80 and 90% (w/w). In other embodiments, the compound is present in an amount of at least 25% (w/w). In some other embodiments, the compound is present in an amount of at least 50% (w/w). In still other embodiments, the compound is present in an amount of at least 75% (w/w). One of skill in the art will appreciate that other compositions are useful in the present invention.

In another embodiment, the compounds of the present invention can be applied onto a stent without a coating. In another embodiment, compounds of the present invention can be applied onto a stent in combination with a polymer coating such as a compounds of the present invention-polymer matrix. The compounds of the present invention can be fully or partially crystallized or in an amorphous form. The polymer can be non degradable, partially degradable or fully degradable. The coating can also be a non-polymeric such as metallic coating. In another embodiment, the compounds of the present invention can be applied on a stent alone or contained in a coating with a polymer or non polymer topcoat. In another embodiment, the stent includes an underlayer coating disposed between the stent surface and the compounds of the present invention or compounds of the present invention-polymer matrix. Suitable underlayer coatings can be poly-

meric such as paralyne C, parylene N, ethylene vinyl alcohol (EVOH), polycaprolactone, ethylvinyl hydroxylated acetate (EVA), or others or combination thereof or non polymeric such as metallic or ceramic or others.

The coatings can be applied by any of the different methods which include but are not limited to spraying, ultrasonic deposition, dipping, inkjet dispersion, plasma deposition, ion implantation, sputtering, evaporation, vapor deposition, pyrolysis, electroplating, glow discharge coating, or others or combination thereof.

The coating thickness can range from 1 nanometer to 100 micrometers, preferably from 100 nanometers to 50 micrometers, more preferably from 1 micrometer to 20 micrometers.

The compounds of the present invention can be combined with antioxidants or stabilizers to prevent degradation due to oxidation or other means. Antioxidants include but are not limited to butylated hydroxytoluene (BHT), ferrous sulfate, ethylenediamine-tetra-acetic acid (EDTA), or others. Stabilizers include, but are not limited to, amylene, hydroquinone, quinine, sodium metabisulfite or others. Antioxidants and stabilizers can be combined with the compounds directly or blended with the compound formulation such as compound-polymer matrix to reduce conformation change or degradation during manufacturing processes and increase shelf life or storage life of the compounds or compound containing implant. The amount of antioxidants such as BHT in the compounds can range from 0.01% to 10%, preferable from 0.05% to 5% and most preferable from 0.1% to 1%. The amount of stabilizers such as amylene in the compounds can range from 0.001% to 0.1%, preferably from 0.005% to 0.05%, most preferably from 0.01% to 0.02%. One of skill in the art will appreciate that other antioxidants and stabilizers are useful in the present invention.

The compounds of the present invention can be administered in combination with a therapeutic agent such as anti-platelet, anti-thrombotic, anti-inflammatory, anti-angiogenic, anti-proliferative, immunosuppressant, anti-cancer or other agents or combinations thereof. One of skill in the art will appreciate that other therapeutic agents are useful in the present invention.

The therapeutic agents can be incorporated on the stent together with the compounds of the present invention and/or separately from compounds of the present invention. At least a portion of the therapeutic agent can be released from the stent prior to, concurrently or post release of the compounds of the present invention from the stent. The therapeutic agent can also be given separately through systemically or site specific administration prior to, during or post delivery of compounds of the present invention.

For example, compounds of the present invention are given with anti platelets or anti-thrombotics such as heparin, clopidogrel, coumadin, aspirin, ticlid or others. In another example, compounds of the present invention are given with anti-inflammatory agents such as aspirin, diclofenac, indomethacin, sulindac, ketoprofen, flurbiprofen, ibuprofen, naproxen, piroxicam, tenoxicam, tolmetin, ketorolac, oxaprosin, mefenamic acid, fenoprofen, nambumetone (relafen), acetaminophen, and mixtures thereof; COX-2 inhibitors, such as nimesulide, NS-398, flosulid, L-745337, celecoxib, rofecoxib, SC-57666, DuP-697, parecoxib sodium, JTE-522, valdecoxib, SC-58125, etoricoxib, RS-57067, L-748780, L-761066, APHS, etodolac, meloxicam, S-2474, tacrolimus, and mixtures thereof; glucocorticoids, such as hydrocortisone, cortisone, prednisone, prednisolone, methylprednisolone, meprednisone, triamcinolone, paramethasone, fluprednisolone, betamethasone, dexam-

ethasone, fludrocortisone, desoxycorticosterone, or others or analogues of the above or combinations thereof.

In some embodiments, the compounds of the present invention are combined with at least one therapeutic agent for treatment of an ophthalmic condition or disorder. Any suitable therapeutic agent known to one of skill in the art can be combined with the compounds of the present invention for use in the treatment of ophthalmic conditions or diseases. Therapeutic agents that can be combined with the compounds of the present invention include, but are not limited to, luten- 5 tis, avastin, macugan, volociximab, olopatadine, mydratics, dexamethasone, pilocarpine, tropicamide, quinolone, galen- 10 tamine, fluocinolone acetonide, triamcinolone acetonide, atropine, atropine sulfate, atropine hydrochloride, atropine methylbromide, atropine methylnitrate, atropine hyperduric, atropine N-oxide, phenylephrine, phenylephrine hydrochloride, hydroxyamphetamine, hydroxyamphetamine hydrobromide, hydroxyamphetamine hydrochloride, hydroxyamphet- 15 amine iodide, cyclopentolate, cyclopentolate hydrochloride, homatropine, homatropine hydrobromide, homatropine hydrochloride, homatropine methylbromide, scopolamine, scopolamine hydrobromide, scopolamine hydrochloride, scopolamine methylbromide, scopolamine methylnitrate, scopolamine N-oxide, tropicamide, tropicamide hydrobromide, tropicamide hydrochloride, pilocarpine, isopilo- 20 carpine, physostigmine, and quaternary ammonium compounds including stearyl ammonium chloride and benzyl ammonium chloride, including mixtures, ionic salts, and combinations thereof.

Formulations of the compounds of the present invention for ophthalmic uses can include any polymer described above. The polymers useful in such formulations can be of any size. In some embodiments, the polymers can have a molecular weight of between about 50 kilo Daltons (kD) and 8,000 kD. One of skill in the art will appreciate that polymers of other sizes are useful in the present invention. 30

In some embodiments, the compounds of the present invention can be administered alone or as part of compound-polymer formulation, compound-solvent formulation or compound-carrier formulation. All formulations of the present invention may include active and inactive ingredients. Active ingredients include, but are not limited to, anti-inflammatory agents, immunomodulating agent and anti-infective agents, antioxidants, antibody, antibiotics, anti-angiogenics, anti-vascular endothelial growth factor agent, antihistamines and lubricant. Inactive ingredients include, but are not limited to, carrier, solvent, inorganic materials, pH-adjustor, radio- 40 opaque, radioactive, fluorescent, NMR contrast or other "reporter or indicator" materials. Examples of solvent in the compound-solvent formulation include, but are not limited to, water, saline, alcohol, and dimethyl sulfoxide. Examples of carrier in the compound-carrier formulation are glycerin, paraffin, beeswax, ethylene glycol, propylene glycol, poly- 45 ethylene glycol, and macrogels. Examples of inorganic materials include, but are not limited to, boric acid, calcium chloride, magnesium chloride, potassium chloride, sodium chloride, zinc chloride, sodium borate, povidone, and dibasic sodium phosphate. Examples of pH-adjustor include, but are not limited to, sodium hydroxide, hydrogen chloride, buffer, and other inorganic and organic acid/base. Examples of preservative include, but are not limited to, benzalkonium chlo- 50 ride, and a polyquaternium. Examples of lubricant include, but are not limited to, carboxymethylcellulose sodium, polyethylene glycol, propylene glycol and ethylene glycol. One of skill in the art will appreciate that other active and inactive ingredients, as well as solvents and carriers are useful in the present invention. 65

In some embodiments, the present invention provides a composition where less than about 5% of the compound is metabolized to rapamycin. In some other embodiments, less than about 1% of the compound is metabolized to rapamycin. In still other embodiments, less than about 0.1% of the compound is metabolized to rapamycin. 5

In other embodiments, the present invention provides a composition in a dosage form, having a daily systemic dose of the compound of from about 0.1 mg to about 20 mg. In some other embodiments, the daily systemic dose of the compound is from about 0.5 mg to about 10 mg. In another embodiment, the daily systemic dose of the compound is from about 1 mg to about 5 mg. 10

IV. Treatment

The compounds of the present invention can be used to treat conditions responsive to the class of compounds commonly known as macrocyclic trienes or macrocyclic lactones. 15

The compounds of the present invention can be used to treat diseases in mammals alone or in combination with other agents, including conditions such as: 20

- a) Treatment and prevention of acute or chronic organ or tissue transplant rejection, e.g. for the treatment of recipients of heart, lung, combined heart-lung, liver, kidney, pancreatic, skin or corneal transplants. They can also be used for the prevention of graft-versus-host disease, such as following bone marrow transplantation.
- b) Treatment and prevention of transplant vasculopathies, e.g. atherosclerosis.
- c) Treatment and prevention of cell proliferation and migration leading to vessel intimal thickening, blood vessel obstruction, obstructive vascular atherosclerosis, restenosis.
- d) Treatment and prevention of autoimmune disease and of inflammatory conditions, such as inflammatory conditions with an etiology including an autoimmune component such as arthritis (for example rheumatoid arthritis, arthritis chronica progrediente and arthritis deformans) and rheumatic diseases.
- e) Treatment and prevention of asthma.
- f) Treatment of multi-drug resistance conditions such as multidrug resistant cancer or multidrug resistant AIDS.
- g) Treatment of proliferative disorders, e.g. tumors, cancer, hyperproliferative skin disorder and the like.
- h) Treatment of infections such as fungal, bacterial and viral.
- i) Treatment or prevention of cellular proliferation in vascular shunts.
- j) Treatment or prevention of ophthalmic conditions and diseases.
- k) Prevention of neo-vascularization.

The potency of Compound AR and rapamycin (Sirolimus) for inhibiting human cell proliferation is demonstrated in an in vitro model. The test is described in Example 2 and the results are shown in FIG. 8. Compound AR inhibited growth of smooth muscle cells over a range of concentrations as demonstrated in FIG. 8. 25

In some embodiments, the present invention provides a method of inhibiting cell proliferation or migration by administering to a subject in need thereof, a therapeutically effective amount of a compound of the present invention. 30

In other embodiments, the present invention provides a method wherein the compound of the present invention is administered systemically, locally or via a combination thereof. 35

In some other embodiments, the administration of the compound of the present invention is via oral administration, administration as a suppository, topical contact, parenteral, 40

intravascular, intravenous, intraperitoneal, intramuscular, intralesional, intranasal, pulmonary, mucosal, transdermal, ophthalmic, subcutaneous administration or intrathecal administration.

In still other embodiments, the administration of the compound of the present invention is via delivery through a temporary device or an implant. In another embodiment, the temporary device is selected from the group consisting of a catheter and a porous balloon. In still another embodiment, the implant is a vascular prosthesis. In yet other embodiments, the vascular prosthesis comprises an expandable structure. In another embodiment, the vascular prosthesis comprises a stent, graft, or a scaffold formed at least in part from an open lattice.

In one embodiment, the inhibition concentration (IC_{50}) of compounds of the present invention is approximately equal to the IC_{50} of its corresponding parent macrocyclic lactone (prior to the modifications in FIG. 1). In another embodiment, the IC_{50} is higher than the IC_{50} of its corresponding parent macrocyclic lactone. In yet another embodiment, the IC_{50} is lower than the IC_{50} of its corresponding parent macrocyclic lactone. For example, the IC_{50} is two to thousand times lower than the IC_{50} of its corresponding parent macrocyclic lactone.

In a preferred embodiment, the IC_{50} of a compound of the present invention is 1.5 to 1,000 times higher than its corresponding parent macrocyclic lactone, preferably 2 to 100 times higher than the corresponding parent macrocyclic lactone and more preferably 5 to 50 times higher than the corresponding parent macrocyclic lactone. In another embodiment the IC_{50} of a compound of the present invention is from about 0.1 nM to about 1 μ M, preferably from about 1 nM to about 0.5 μ M, more preferably from about 5 nM to about 100 nM.

Other means of measuring the effectiveness of the compounds of the present invention include measuring effective concentration (EC_{50}). In one embodiment, the EC_{50} is approximately equal to the EC_{50} of the corresponding parent macrocyclic lactone. In another embodiment, the EC_{50} is higher than the EC_{50} of the corresponding parent macrocyclic lactone. In yet another embodiment, the EC_{50} is lower than the EC_{50} of the corresponding parent macrocyclic lactone.

In some embodiments, the present invention provides a method wherein the effective dose of the compound is from about 0.1 mg to about 20 mg. In some other embodiments, the effective dose of the compound is from about 0.5 mg to about 10 mg. In still other embodiments, the effective dose of the compound is from about 1 mg to about 5 mg.

The compounds, compositions and devices of the present invention are useful for cytokine inhibition. Pro-inflammatory cytokine IL-6 is synthesized in response to diverse inflammatory stimuli and acts as a key regulatory protein in the inflammatory cascade. IL-6 plays a pivotal role in stimulating the acute-phase response after injury, including the release of fibrinogen and C-reactive protein.

IL-6 may also be directly involved in restenosis, as it has been shown to stimulate leukocyte recruitment into the vessel wall, and vascular smooth muscle cell proliferation, factors that are essential to the pathogenesis of hyperproliferative diseases such as restenosis.

Matrix metalloproteinases (MMP-9) play a key role in cellular migration and proliferation including conditions such as neointimal growth and vascular remodeling after stent implantation. Release of MMPs cause increases in proteoglycan rich, extracellular matrix which increases smooth muscle cell migration after vascular injury.

Plasma active MMP-9 levels may be a useful independent predictor of bare metal stent ISR. (Elevated Plasma Active

Matrix Metalloproteinase-9 Level Is Associated With Coronary Artery In-Stent Restenosis, *Arterioscler Thromb Vasc Biol.* 2006;26:e121-e125.)

Monocyte chemoattractant protein 1 (MCP-1) is a potent monocyte chemoattractant secreted by many cells in vitro, including vascular smooth muscle and endothelial cells. Eliminating MCP-1 gene or blockade of MCP-1 signals has been shown to decrease atherogenesis in hypercholesterolemic mice. MCP-1 has been shown to play a role in pathogenesis of neointimal hyperplasia in monkeys. (Importance of Monocyte Chemoattractant Protein-1 Pathway in Neointimal Hyperplasia After Periarterial Injury in Mice and Monkeys, *Circ Res.* 2002;90:1167-1172.) MCP-1 is also strongly expressed in a small subset of cells in macrophage-rich regions of human and rabbit atherosclerotic lesions (Expression of Monocyte Chemoattractant Protein 1 in Macrophage-Rich Areas of Human and Rabbit Atherosclerotic Lesions, *PNAS*, Vol 88, 5252-5256) Inhibition of MCP-1 can have therapeutic impact on treatment and prevention of inflammatory, proliferative and other disease conditions discussed above.

Interleukin-10 (IL-10) is an anti-inflammatory cytokine with a powerful inhibitory effect on monocytes. IL-10 has been shown to reduce postinjury intimal hyperplasia (Interleukin-10 Inhibits Intimal Hyperplasia After Angioplasty or Stent Implantation in Hypercholesterolemic Rabbits *Circulation.* 2000;101:908-916). Endogenous production of IL-10 by human monocytes in response to LDL stimulation inhibits IL-12 production, indicating a cross-regulatory action of IL-10 that may counterbalance the proinflammatory response.

A. Ophthalmic Conditions and Diseases

In some embodiments, the compounds, pharmaceutical compositions and devices of the present invention are useful for the treatment of ophthalmic conditions and diseases. The compounds, pharmaceutical compositions and devices of the present invention are useful in the treatment of any ophthalmic condition or disease. Ophthalmic conditions and diseases that can be treated by the compounds and devices of the present invention include, but are not limited to, disorders of the eyelid, disorders of the lacrimal system and orbit, tear duct blockage, disorders of conjunctiva, disorders of the sclera, cornea, iris and ciliary body, disorders of the lens, disorders of the choroid and retina, Age-related Macular Degeneration (AMD), Diabetic Macular Edema (DME), glaucoma, disorders of the vitreous body and globe, disorders of the optic nerve and visual pathways, disorders of the ocular muscles, binocular movement, accommodation and refraction, visual disturbances and blindness, etc. Additional ophthalmic conditions and diseases that can be treated with the compounds and devices of the present invention include inhibition of cell proliferation, prevention of inflammation, prevention of neovascularization, protection of neurovascular system, and prevention of immune response after transplantation. One of skill in the art will appreciate that other ophthalmic conditions and diseases can be treated using the compounds and devices of the present invention.

Current treatment methods include surgery and medications. Surgical treatment methods include retinal implant, high speed laser eye surgery, endothelial keratoplasty, cataract surgery, glaucoma surgery, refractive surgery, corneal surgery, vitreo-retinal surgery, eye muscle surgery, oculoplastic surgery, uses of stem cells to create corneas or part of corneas that can be transplanted into the eyes.

Ophthalmic conditions and diseases can be treated using compounds, pharmaceutical compositions and devices of the present invention, as described above. The compounds and

pharmaceutical compositions of the present invention can be administered via any method known to one of skill in the art. In some embodiments, the compounds of the present invention are administered via implant, injection or eye drop. In some other embodiments, the administration is through an intraocular or intravitreal body of the eye. In other embodiments, the administration is via the implant. In other embodiments, the compounds are administered via an implant where the compound is released via a metallic, ceramic or polymer coating.

When administration is via the implant, the compound can be released by any means known in the art. In some embodiments, release of the compound from the implant can be via osmotic pressure or diffusion. One of skill in the art will appreciate that other means of releasing the compound from the implant are useful in the present invention.

In some embodiments, the compounds of the present invention are combined with at least one other therapeutic agent for treatment of an ophthalmic condition or disorder. Any suitable therapeutic agent known to one of skill in the art can be combined with the compounds of the present invention for use in the treatment of ophthalmic conditions or diseases. In some embodiments, the therapeutic agents include, but are not limited to, anti-inflammatory agents, immunomodulating agent and anti-infective agents, antioxidants, antibody, antibiotics, anti-angiogenics, anti-vascular endothelial growth factor agent, antihistamines and lubricant. Therapeutic agents that can be combined with the compounds of the present invention include, but are not limited to, lucentis, avastin, macugan, volociximab, olopatadine, mydratics, dexamethasone, pilocarpine, tropicamide, quinolone, galentamine, fluocinolone acetonide, triamcinolone acetonide, atropine, atropine sulfate, atropine hydrochloride, atropine methylbromide, atropine metilnitrate, atropine hyperduric, atropine N-oxide, phenylephrine, phenylephrine hydrochloride, hydroxyamphetamine, hydroxyamphetamine hydrobromide, hydroxyamphetamine hydrochloride, hydroxyamphetamine iodide, cyclopentolate, cyclopentolate hydrochloride, homatropine, homatropine hydrobromide, homatropine hydrochloride, homatropine methylbromide, scopolamine, scopolamine hydrobromide, scopolamine hydrochloride, scopolamine methylbromide, scopolamine metilnitrate, scopolamine N-oxide, tropicamide, tropicamide hydrobromide, tropicamide hydrochloride, pilocarpine, isopilocarpine, physostigmine, and quaternary ammonium compounds including stearyl ammonium chloride and benzyl ammonium chloride, including mixtures, ionic salts, and combinations thereof.

It can be appreciated that all embodiments disclosed in the present invention can be utilized alone or in combination with other embodiments or examples in this invention.

V. Examples

Example 1

Preparation of 16-O-demethyl Macrocylic Lactone (Compound AR)

Macrocylic lactone rapamycin (1000 mg, 10.75 mmol) in 500 ml acetonitrile was treated with 500 ml 0.1N hydrochloric acid. The resulting solution was stirred at room temperature for about 28 hours. Then the reaction mixture was extracted with dichloromethane in a separatory funnel. The organic layers were washed with water and brine, then washed with 0.1M sodium phosphate buffer (pH=7.4) twice or until pH=7, then washed three times with distilled (DI) water. Finally the organic layer was dried over Na₂SO₄ and

placed in a refrigerator overnight. Concentration in vacuum provided an off-white powder of Compound AR (approx. 820 mg).

Compound AR was purified by preparative HPLC on an Ascentis C18 (21.2 ×250 mm, 10 μm) column from SUPECO using Methanol:water (80:20) as mobile phase from 0-12 min then changed to 100% Methanol from 12.01-20 min at a flow rate of 15 ml/min. The loading concentration was 350 mg/ml and the injection volume was 100 μl. The compound was monitored by UV absorbance at 254 nm. Under these conditions, Compound AR eluted between 9.0-11.5 min whereas the starting materials and by products eluted between 17.0-20.0 min.

The preparative HPLC can also be conducted using a gradient of acetonitrile:water (starting from 70:30) as mobile phase and monitored by UV absorbance at 278 nm. The preparative HPLC chromatogram using this method of separation is shown in FIG. 4.

The fractions containing Compound AR were collected and pooled together, then solvent was evaporated by using a rotovac and freeze drier to give an off-white powder of Compound AR.

¹H NMR (CDCl₃, 400 MHz, mixture of trans:cis amide rotamers, chemical shifts in parentheses refer to the major rotamer) is presented in FIG. 5. δ, ppm 0.532 (q, J=12 Hz, 1H), 0.890 (d, J=6.8 Hz, 3H), 0.921 (d, J=6.8 Hz, 3H), 0.931 (d, J=6.4 Hz, 3H), 0.971 (d, J=6.8 Hz, 3H), 0.991 (d, J=6.6 Hz, 3H), 1.005 (d, J=6.4 Hz, 3H), 1.686 (s, 3H), 1.772 (s, 3H), 1.773 (s, 3H), 1.823 (s, 3H), 3.330 (s, 3H), 3.380 (s, 3H), 3.859 (d, J=5.2 Hz, 1H), 4.001 (d, J=3.6 Hz, 1H), 4.03-4.07 (m, 1H), 4.22 (br, 1H), 5.21-5.28 (m, 3H), 5.336 (d, J=11.6 Hz, 1H), 5.384 (dd, J=14.8, 9.6 Hz, 1H), 6.117 (dd, J=14.4, 10.8 Hz, 1H), 6.243 (dd, J=14.4, 10.4 Hz, 1H), 6.376 (dd, J=14.8, 11.2 Hz, 1H).

Compared with the proton NMR of the parent compound, the disappearance of the peak at 3.14 ppm demonstrates the demethylation at the C16 position only and completion of reaction. (See *Journal of Antibiotics* 1991, 44(6), 688 for assignment of the NMR spectra for rapamycin.)

The chemical structure of Compound AR was further verified by mass spectrometric experiments. The fragmentation patterns indicated the presence of the m/z 900 whereas Rapamycin provides m/z 914 under the same conditions. The results of liquid chromatography and mass spectroscopy experiments are provided in FIG. 6 which shows the identification of Compound AR with m/z 900.

The total content of Compound AR was determined by a reverse phase HPLC using a Supelco C18 (4.6×150 mm, 5 μm) column from Sigma Aldrich using methanol:water (90:10) as mobile phase and a flow rate of 1 ml/min. Compound AR was monitored by UV absorbance at 254 nm. Compound AR had a retention time of 7.97 min. FIG. 7 shows the analytical HPLC chromatogram of Compound AR with total content of >98%. The purity of Compound AR was determined by a reverse phase HPLC using a YMC ODS-AL C18 (4.6×250 mm, 5 μm) column from Waters Corporation using an acetonitrile:water gradient mobile phase and a flow rate of 1.0 ml/min. FIG. 7b shows major isomers of Compound AR with a purity >98% as monitored by UV absorbance at 278 nm.

As a means to minimize oxidation of the Compound AR, 0.1% w/w of Butylated Hydroxytoluene (BHT) was added after preparative HPLC.

Example 2

Biological Activity of Compound AR

Potency of the Compound AR was demonstrated by in vitro human smooth muscle cell culture testing. The amounts of

incorporated thymidine for samples of Compound AR of varying concentrations (0.005, 0.01, 0.05, 0.1, 0.5, and 1 μ M) and of rapamycin of varying concentrations (0.0005, 0.001, 0.01, and 0.1 μ M) were measured after exposure for different times of 1, 3 and 8 hours. The IC_{50} for Compound AR and rapamycin were approximately 0.05 and 0.01 μ M, respectively, after smooth muscle cells were exposed to Compound AR and rapamycin for the shorter periods of 1 and 3 hours (as shown in Table I and FIG. 8). The IC_{50} of Compound AR and rapamycin was approximately 0.005 and 0.001 μ M, respectively, after smooth muscle cells were exposure to Compound AR and rapamycin for 8 hours. The IC_{50} of Compound AR was approximately five times higher than that of rapamycin.

TABLE I

Data of percentage proliferation of human smooth muscle cells after exposure to varying concentrations of rapamycin and Compound AR					
Compound AR					
Concentration (micromolar)	0.005	0.01	0.05	0.1	0.5
% Proliferation After One Hr Exposure to Compound AR	84	66	54	55	57
% Proliferation After Three Hr Exposure to Compound AR	69	56	50	52	48
% Proliferation After Eight Hr Exposure to Compound AR	52	38	40	36	35
Rapamycin					
Concentration (micromolar)	0.0005	0.001	0.01	0.1	
% Proliferation After One Hr Exposure to Rapamycin	105	75	54	50	
% Proliferation After Three Hr Exposure to Rapamycin	79	63	48	39	
% Proliferation After Eight Hr Exposure to Rapamycin	57	51	40	38	

Example 3

Preparation of Stents Containing Compound AR

15 mg poly(n-butyl methacrylate) (PBMA) was dissolved into 3 mL dichloromethane at room temperature. 10 mg of Compound AR was placed in a vial and dissolved in 2 mL dichloromethane with or without 0.1% (w/w) BHT. The solutions were combined and further diluted with 10 mL dichloromethane.

A microprocessor-controlled ultrasonic sprayer was used to apply 450 μ g of the drug containing PBMA solution to the entire surface of 1.5 mm metal stent (available from Elixir Medical Corp, Sunnyvale, Calif.). After coating, the stent was placed in a vacuum 15 chamber. The stent was then mounted on the balloon of a 3.0 \times 20 mm PTCA delivery catheter. The catheter was then inserted in a coil and packaged in a Tyvek® pouch. The pouch was sterilized by ethylene oxide. The Tyvek® pouch was further packaged in a foil pouch with oxygen scavengers and nitrogen purge and vacuum sealed.

Example 4

In vivo Testing of Stents Eluting Compound AR

The efficacy of a Compound AR eluting stent system (as prepared above) from Example 3 was evaluated by comparing 28 \pm 2 day angiographic outcomes in porcine coronary arteries

to the rapamycin eluting stent system, Cypher™ Coronary Stent (Cordis Corporation) in the non-diseased porcine coronary artery model.

The nonatherosclerotic swine model was chosen as this model has been used extensively for stent and angioplasty studies resulting in a large volume of data on the vascular response properties and its correlation to human vascular response (Schwartz et al, Circulation. 2002;106:1867-1873). The animals were housed and cared for in accordance the Guide for the Care and Use of Laboratory Animals as established by the National Research Council.

All animals were pretreated with aspirin (325 mg) and clopidogrel (75 mg) per oral dose beginning at least 3 days prior to the intervention and continuing for the duration of the study. After induction of anesthesia, the left or right femoral artery was accessed using standard techniques and an arterial sheath was introduced and advanced into the artery.

Vessel angiography was performed under fluoroscopic guidance, a 7 Fr. guide catheter was inserted through the sheath and advanced to the appropriate location where intracoronary nitroglycerin was administered. A segment of coronary artery ranging from 2.25 to 4.0 mm mean lumen diameter was chosen and a 0.014" guidewire inserted. Quantitative Coronary Angiography (QCA) was performed to document the reference vessel diameter.

The appropriately sized stent was advanced to the deployment site. The balloon was inflated at a steady rate to a pressure sufficient to achieve a balloon to artery ratio of 1.30:1.0. Pressure was maintained for approximately 10 seconds. Angiography was performed to document post-procedural vessel patency and diameter.

Follow-up angiography was performed at the designated endpoint for each of the animals. Each angiogram was qualitatively evaluated for evidence of stent migration, lumen narrowing, stent apposition, presence of dissection or aneurysms, and flow characteristics. Upon completion of follow-up angiography, the animals were euthanized.

The hearts were harvested from each animal and the coronary arteries were perfused with 10% buffered formalin at 100 to 120 mm Hg. The hearts were immersed in 10% buffered formalin. Any myocardial lesions or unusual observations were reported.

Angiographic parameters measured or calculated included:

- Marginal vessel (proximal and distal) mean lumen diameter (post-stent and final only)
- Mean lumen diameter of the target region (all angiograms)
- Minimal lumen diameter (MLD) of the target region (post-stent and final only)
- Diameter stenosis $[1 - (MLD/RVD)] \times 100\%$ where RVD is a calculation of the reference diameter at the position of the obstruction (measure obtained by a software-based iterative linear regression technique to generate an intrapolation of a projected vessel without the lesion) (final angiogram only)
- Balloon to artery ratio [balloon/pre-stent mean luminal diameter]
- Stent to artery ratio [post-stent/pre-stent mean luminal diameter]
- Late loss ratio [MLD final-MLD post-stent]

All animal survived to the designated end point. There were no documented incidents of stent migration, stent malapposition, persistent dissection or evidence of aneurysm. Three outlying data points (total occlusion or near total occlusion) for the Cypher

Stent were excluded. The average percent stenosis for the Compound AR stent (approx. 10 microgram/mm length drug

91

dose) was 25.7 ± 17.8 ($n=15$) as compared to Cypher Stent pooled data from this and previous studies with similar protocols which provided an average percent stenosis of 20.21 ± 11.45 ($n=22$) for Cypher stents. (FIG. 9).

The Compound AR eluting stents in this example when implanted in the porcine model for 28 days resulted in higher percentage stenosis as compared to the Cypher Stent.

Example 5

In vivo Pharmacokinetics of Stents Eluting Compound AR

Pharmacokinetic evaluation of the Compound AR stent system from Example 3 was performed at 6 hours, 3 days, 7 days, and 28 days in the porcine coronary artery model. The interventional procedures used were similar to the in vivo angiographic study described in Example 4 up to stent implantation.

The appropriately sized stent was advanced to the deployment site. The balloon was inflated at a steady rate to a pressure sufficient to achieve a balloon to artery ratio of 1:1. Pressure was maintained for approximately 10 seconds. Angiography was performed to document post-procedural vessel patency and diameter. A total of 9 stents (3 per time point) were implanted.

At the appropriate time point the animals were euthanized and the hearts excised. The stented segment including approximately 10 mm of vessel proximal and 10 mm distal to the stented section was excised. The proximal and distal sections were separated and stored in separate vials. The tissue surrounding the stent was carefully removed from stent and each placed in separate vials. All were then frozen to -70°C . prior to being analyzed using liquid chromatography mass spectroscopy (LCMS).

All animal survived to the designated end point. The average tissue concentrations for the Compound AR and stent release rates are presented in FIGS. 10 and 11. The Compound AR eluting stent, in this example demonstrates release of Compound AR from the stent with greater than 40% of the drug released at 7 days.

Example 6

Preparation of 17, 18-29, 30-bis-epoxide Macrocylic Lactone (AS)

Add 0.8 mL 5% NaOH-MeOH and 2 ml 30% H_2O_2 to a solution of 1 gram rapamycin in 40 ml methanol. The reaction mixture was stirred at room temperature for 24 hours. If TLC indicated some rapamycin was still unreacted, additional mixture of 0.8 mL 5% NaOH-MeOH and 2 ml 30% H_2O_2 was added to the reaction solution. Stirring continued at room temperature until TLC indicated the reaction has completed. The solution was extracted with dichloromethane and brine 3 times. The organic layers were combined and washed with brine and water, dried over anhydrous MgSO_4 , filtered MgSO_4 and the solution was evaporated to leave a raw product. This raw product was further purified using TLC plate and giving 0.40 g (40% yields) light yellow powder. ^1H NMR (CDCl_3) (~4:1 mixture of conformers, only signals of major conformer listed) Major changes compared with rapamycin $\delta(\text{ppm})$ 1.75(s, 1H), 1.98(s, 1H), 6.71(ddd, 5H, $J_1=16$ Hz, $J_2=8$ Hz, $J_3=2.8$ Hz). ^{13}C DEPT 135 NMR (CDCl_3) (~4:1 mixture of conformers, only signals of major conformer listed) $\delta(\text{ppm})$ 152, 140, 133, 128, 127, 126, 84, 83, 76, 74, 67,

92

59, 56, 44, 43, 41, 40, 36, 35, 34, 33, 31, 29, 28, 22, 21, 20, 17, 16, 15, 13. Mass Spectra $m/z=962$ with rapamycin $m/z=930$.

Example 7

Biological Activity of 17, 18-29, 30-bis-epoxide Macrocylic Lactone (AS)

Potency of the 17, 18-29, 30-bis-epoxide macrocylic lactone was demonstrated by in vitro human smooth muscle cell culture testing. The amounts of incorporated thymidine for samples of 17, 18-29, 30-bis-epoxide macrocylic lactone of varying concentrations (0.005, 0.01, 0.05, 0.1, 0.5, and 1 μM) and of Compound AR of varying concentrations (0.0005, 0.001, 0.01, and 0.1 μM) were measured after exposure for 8 hours. The IC_{50} of 17, 18-29, 30-bis-epoxide macrocylic lactone and Compound AR was approximately 0.1 and 0.005 μM , respectively, after smooth muscle cells were exposed to 17, 18-29, 30-bis-epoxide macrocylic lactone and Compound AR for 8 hours (FIG. 13). The IC_{50} of 17, 18-29, 30-bis-epoxide macrocylic lactone was approximately 20 times higher than that of Compound AR.

Example 8

Preparation of 17, 18-19, 20-21, 22-tris-epoxide Macrocylic Lactone (AY)

m-chloro-peroxybenzoic acid 0.93 g (3.22 mmol) was added to a solution of 0.50 g (0.5371 mmol) rapamycin in 10 ml CHCl_3 at room temperature. The mixture was stirred at room temperature for 24 hours. If TLC indicated some rapamycin was still unreacted, additional m-chloroperoxybenzoic acid 0.50 g and 5 mL CHCl_3 was added. Stirring was continued at room temperature until no Rapamycin was indicated by TLC. After completion of the reaction, the solution was diluted with dichloromethane, treated with aqueous sodium sulfite until the washings give a negative test with starch-iodide paper. This ensures all excess peracid has been destroyed and the aqueous layer was extracted with several portions of CH_2Cl_2 . Then organic layer was washed with two 20 ml portion of 5% sodium bicarbonate to remove benzoic acid. The combined organic extracts were washed with water, dried with anhydrous MgSO_4 , filtered and evaporated to leave a crude white solid 0.46 g. The raw product was further purified using TLC plate. MS m/z 978 with Rapamycin m/z 930.

Example 9

Cytokine Inhibition by Macrocylic Lactone:

In cell culture studies, macrophages were activated to secrete cytokines such as IL-6, MMP-9, MCP-1 and IL-10 by treating the cells to *E. Coli* lipopolysaccharide (LPS). Inhibition of these cytokines upon treatment of the activated macrophages with Compound AR and rapamycin with 10 nM concentration was tested using ELISA assay. The inhibition of pro-inflammatory and cell proliferation and migration inducing cytokines upon exposure to the macrocylic lactone is presented in FIG. 12(a). The inhibition of anti-inflammatory cytokine IL-10 upon exposure to macrocylic lactone Compound AR and sirolimus are presented in FIG. 12(b). MMP-9 levels in the 1st, 3rd and 7th day after stent implantation were positively correlated to the late loss index 6 months after stent implantation (Elevated matrix metallo-

proteinase expression after stent implantation is associated with restenosis. *Int J Cardiol.* 2006; 112(1):85-90).

Compound AR and sirolimus did not show any significant inhibition of release of IL-6. Compound AR significantly reduced the production of both the cytokines MMP-9 and MCP-1 as compared to sirolimus which increased the production of MMP-9 and did not impact the production of MCP-1.

Compound AR and sirolimus did not show any difference in inhibition of release of IL-6. On the other hand, Compound AR reduced the production of cytokine MMP-9 while sirolimus increased the production of MMP-9. Compound AR reduced the production of cytokine MCP-1 as compared to sirolimus which did not impact the production of MCP-1. Compound AR and sirolimus both inhibit the production of anti-inflammatory cytokine IL-10.

Compounds claimed in the present invention, such as Compound AR can provide better therapeutic response with higher levels of anti-inflammatory effect (such as greater inhibition of pro-inflammatory cytokine MCP-1) and higher levels of anti-cell proliferative and anti-cell migratory effect (such as greater inhibition of pro-proliferative and migration cytokine MMP-9).

Example 10

Testing of Compound AR Eluting Stents in Human Clinical Trial:

Clinical testing of the Compound AR coated stent was conducted on 15 human subjects. Safety of the Compound AR coated stent was evaluated clinically through the evaluation of major adverse cardiac events defined as: death, myocardial infarction (both Q-wave and non-Q-wave), and target lesion revascularization. Efficacy was evaluated through angiographic and intravascular ultrasound (IVUS) results at 4 months. The primary endpoint of the study was angiographic in-stent late lumen loss. Secondary endpoints were Major Adverse Cardiac Events (MACE) and additional angiographic and IVUS evaluation. The clinical study was approved by local Ethics Committee and all patients signed an Ethics approved informed consent before entry into the clinical study.

All patients were pretreated with aspirin and ticlopidine (500 mg) per oral beginning at least 1 day prior or on the day of the index procedure. Aspirin (>100 mg/day and Clopidogrel (75 mg/day) were continued through for at least six months. In accordance with hospital standard percutaneous practice, the left or right femoral artery was accessed using standard techniques and an arterial sheath was introduced and advanced into the artery.

Index procedure vessel angiography was performed under fluoroscopic guidance, a 6 or 7 Fr. guide catheter was inserted through the sheath and advanced to the appropriate location; intracoronary nitroglycerin was administered. A segment of coronary artery ranging from 3.0 mm to 3.5 mm mean lumen diameter was chosen and a 0.014" guidewire inserted. Quantitative Coronary Angiography (QCA) was performed to document the reference vessel diameter. Predilatation of the lesion was performed prior to stent implantation using standard technique.

Following predilatation, the appropriately sized stent (3.0×18 mm or 3.5×18 mm) was advanced to the deployment site. The balloon was inflated at a steady rate to a pressure to fully deploy the stent. Pressure was maintained for approximately 30 seconds. Post dilatation of the stent could be performed as needed to assure good stent apposition to the vessel wall. Angiographic and intravascular ultrasound imaging (IVUS) was performed and recorded.

Follow-up angiography and IVUS was performed at the designated endpoint of 4 months for each patient. Each angiogram was qualitatively evaluated for evidence of lumen narrowing, stent apposition, and flow characteristics.

Angiographic and IVUS parameters measured or calculated included:

Marginal vessel (proximal and distal) mean lumen diameter (post-stent and final)

Mean lumen diameter of the target region (all angiograms)

Minimal lumen diameter (MLD) of the target region (post-stent and final only)

Diameter stenosis $[1 - (\text{MLD}/\text{RVD})] \times 100\%$ where RVD is a calculation of the reference diameter at the position of the obstruction (measure obtained by a software-based iterative linear regression technique to generate an interpolation of a projected vessel without the lesion) (final angiogram only).

In-stent Late Lumen Loss $[\text{MLD final} - \text{MLD post-stent}]$

In-stent percent neointimal volume as assessed by IVUS

All patients underwent 4 month clinical and angiographic follow-up. No patients experience any major adverse cardiac events during the follow-up period. Angiographic results demonstrated that the primary endpoint of angiographic in-stent late lumen loss was 0.16 ± 0.32 mm. IVUS analysis was conducted on 13 of 15 patients and the results demonstrated in-stent percent neointimal volume of $3.7 \pm 2.7\%$.

As a comparison, Cypher stent tested in a pilot study and demonstrated similar clinical safety with no clinical events and angiographic results at 4 months of in-stent late lumen loss for the slow release group (the current commercially available formulation) of 0.09 ± 0.3 mm and in-stent percent neointimal volume by IVUS to be $0.3 \pm 0.6\%$ (Sousa, J E, *Circulation* 2001;103:192-195).

Example 11

Preparation of 31-hydroxyl, 44-hydroxyl (Compound BG) and 47-hydroxyl (Compound BJ) Macrocyelic Lactone

Macrocyelic lactone rapamycin (1 g, 1.1 mmol) in 100 ml absolute ethanol was added to selenium dioxide (122 mg, 1.10 mmol) absolute ethanol (50 ml) solution. The mixture was stirred at room temperature until TLC analysis showed the disappearance of rapamycin (about 15 h). The reaction mixture was concentrated and the residue was partitioned between ether and water and extracted with ether 3×80 ml. The organic layers was dried over anhydrous sodium sulfate, filtered and concentrated. The final individual pure product 31-hydroxyl, 44-hydroxyl, 47-hydroxyl macrocyelic lactone were obtained by prepared HPLC.

The characterized spectra changes compared with macrocyelic lactone rapamycin are shown as follows:

95

	Sample name		
	31-hydroxyl macrocylic lactone	44-hydroxyl macrocylic lactone (compound BG)	47-hydroxyl macrocylic lactone (compound BJ)
Mass M/Z [M + H]	929	929	929
¹ HNMR (1:1 THF-d ₈ /D ₂ O)	Loss of 0.87, 3.21, 3.27 ppm peak; Gain 1.38 ppm peak	Loss of 1.58 ppm single peak; Gain 4.07 ppm peak	Loss of 1.72 ppm single peak; Gain 4.07 ppm peak

Example 12

Preparation of 43-hydroxyl(Compound BF),
47-hydroxyl(Compound BJ) Macrocylic Lactone

A solution of 1 gram macrocylic lactone rapamycin (1.1 mmol) was dissolved in 100 ml acetonitrile. 0.3 gram Ferrrous Sulfate heptahydrate (1.1 mmol) was added to the solution with stirring and nitrogen purging for 20-30 minutes. The mixture was then cooled to -16° C. to -18° C. with ice-bath. A solution of 1 ml 30% H₂O₂ in 10 ml acetonitrile was then slowly added to above mixture over 30 min with stirring and nitrogen purging. After complete addition of hydrogen peroxide, continued stirring and nitrogen purging until TLC analysis showed the disappearance of rapamycin. The solution was extracted with dichloromethane and brine 3 times. The organic layer was combined and washed with brine and water, dried over anhydrous MgSO₄, filtered MgSO₄ and the solution was evaporated to leave a raw product. The pure product 43 -hydroxyl, 47-hydroxyl macrocylic lactone were obtained by prepared HPLC.

The characterized spectra changes compared with macrocylic lactone rapamycin are shown as follows:


	Sample name	
	43-hydroxyl macrocylic lactone (compound BF)	47-hydroxyl macrocylic lactone (compound BJ)
Mass M/Z [M + H]	929	929
¹ HNMR, (1:1 THF- d ₈ /D ₂ O)	Loss of 0.74 ppm peak; Gain 3.49, 3.24 ppm peaks	Loss of 1.72 ppm single peak; Gain 4.07 ppm peak

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, one of skill in the art will appreciate that certain changes and modifications may be practiced within the scope of the appended claims. In addition, each reference provided herein is incorporated by reference in its entirety to the same extent as if each reference was individually incorporated by reference.

What is claimed is:

1. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula:

96



and

salts, isomers, and N-oxides thereof.

2. The composition of claim 1, wherein the pharmaceutically acceptable excipient is a member selected from the group consisting of a polymer, a solvent, an antioxidant, a binder, a filler, a disintegrant, a lubricant, a coating, a sweetener, a flavor, a stabilizer, a colorant, a metal, a ceramic and a semi-metal.

3. The composition of claim 2, wherein the pharmaceutically acceptable excipient is a polymer.

4. The composition of claim 3, wherein the polymer is selected from the group consisting of polyurethane, polyethylene imine, ethylene vinyl alcohol copolymer, silicone, C-flex, nylons, polyamide, polyimide, polytetrafluoroethylene (PTFE), parylene, parylax, poly(methacrylate), poly(vinyl chloride), poly(dimethyl siloxane), poly(ethylene vinyl acetate), polycarbonate, polyacrylamide gels, poly(methyl methacrylate), poly(n-butyl methacrylate), poly(butyl methacrylate) copolymer or blended with poly(ethylene vinyl acetate), poly(methyl methacrylate), poly(2-hydroxy ethyl methacrylate), poly(ethylene glycol methacrylates), poly(ethylene carbonate), Poly L lactide-glycolide copolymer, poly L lactide-trimethylene carbonate copolymer and Poly L-lactide.

5. The composition of claim 4, wherein the polymer is poly(n-butylmethacrylate).

6. The composition of claim 4, wherein the compound is present in an amount of at least 25% (w/w) in a mixture of the compound and the polymer.

7. The composition of claim 6, wherein the compound is present in an amount of at least 50% (w/w).

8. The composition of claim 6, wherein the compound is present in an amount of at least 75% (w/w).

9. The composition of claim 1, wherein less than about 5% of the compound is metabolized to rapamycin.

10. The composition of claim 1, wherein less than about 1% of the compound is metabolized to rapamycin.

11. The composition of claim 1, wherein less than about 0.1% of the compound is metabolized to rapamycin.

12. The composition of claim 1 in a dosage form, having a daily systemic dose of the compound of from about 0.1 mg to about 20 mg.

13. The composition of claim 12, wherein the daily systemic dose of the compound is from about 0.5 mg to about 10 mg.

14. The composition of claim 12, wherein the daily systemic dose of the compound is from about 1 mg to about 5 mg.

15. The composition of claim 1, wherein the isomers are stereoisomers at the C-16 position.

* * * * *